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 I 
Zusammenfassung 
 
Das Neuroblastom ist eine maligne Erkrankung des sympathischen Nervensystems und im 
Kindesalter der häufigste extrakranielle solide Tumor. Die klinischen Verläufe sind vielfältig 
und reichen von spontaner Regression oder Differenzierung des Tumors bis zu aggressiven, 
fatalen Verlaufsformen. Unter Berücksichtigung der embryonalen Entwicklung des 
sympathischen Nervensystems wird eine verzögerte Aktivierung apoptotischer Prozesse als 
Grundlage der spontanen Regression im Neuroblastom diskutiert. HOX Gene spielen eine 
entscheidende Rolle bei der embryonalen Entwicklung und sind maßgeblich an den Prozessen 
der Zelldifferenzierung und Apoptose beteiligt.  
In dieser Arbeit wurde anhand eines umfangreichen Datensatzes von 649 
Genexpressionsprofilen primärer Neuroblastome gezeigt, dass die Expression einer Mehrzahl 
der Klasse I HOX Gene signifikant mit klinischen Markern beim Neuroblastom assoziiert ist. 
Die prognostische Bedeutung der HOX Gen Expressionsmuster wurde darüber hinaus durch 
die Beobachtung verdeutlicht, dass eine HOX Gen Expressions-Signatur, unabhängig von den 
derzeit angewandten Prognosemarkern Alter, Stadium und MYCN-Amplifikationsstatus eine 
zuverlässige Vorhersage der Krankheitsverläufe im Neuroblastom ermöglicht.  
In prognostisch günstigen Neuroblastomen, bei denen es regelhaft zu einer spontanen 
Regression kommt, wurde eine auffallend hohe HOXC9 Expression detektiert. Um die 
Bedeutung des Transkriptionsfaktors Hox-C9 für die Pathogenese der unterschiedlichen 
Krankheitsverläufe des Neuroblastoms zu untersuchen, wurden Tetrazyklin-induzierbare 
HOXC9-transgene Neuroblastom-Zelllinien generiert.   
Die Re-expression von HOXC9 führte zu einer verminderten Zellviabilität und 
inhibierte das Tumorwachstum in einem Xenograft-Maus-Modell nahezu vollständig. Eine 
signifikante Zunahme der Sub-G1 Zellfraktion und die Translokation von Phosphatidylserin 
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auf die Außenseite der Zellmembran deuten auf apoptotische Vorgänge hin. In diesem 
Zusammenhang wurde nach Hox-C9 Induktion ein erhöhter BAX/BCL-2 Quotient, eine 
erhöhte Ausschüttung von Cytochrom c aus den Mitochondrien und eine Aktivierung der 
intrinsichen Caspase Kaskade nachgewiesen. Des Weiteren zeigte sich, dass die Expression 
von HOXC9 zu einer signifikanten Abnahme der Proliferation in den untersuchten Zelllinien 
führte, was durch einen Zellzyklusarrest in der G0/G1 Phase erklärt wurde. Soft-Agar 
Analysen zeigten außerdem eine Einschränkung des kontaktunabhängigen Wachstums nach 
Hox-C9 Induktion. In einer von drei untersuchten Zelllinien wurde nach Hox-C9 Induktion 
eine zunehmende morphologische Differenzierung der Neuroblastomazellen detektiert.  
Zusammenfassend zeigt diese Arbeit einen starken prognostischen Einfluss von HOX 
Genen im Neuroblastom im Allgemeinen, und weist auf eine Bedeutung des 
Transkriptionsfaktors Hox-C9 bei den Prozessen der spontanen Regression des 
Neuroblastoms hin.  
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Summary 
 
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system. Spontaneous 
regression and differentiation of neuroblastoma is observed in a subset of patients, and has 
been suggested to represent delayed activation of physiologic molecular programs of fetal 
neuroblasts. Homeobox genes constitute an important family of transcription factors which 
play a fundamental role in morphogenesis and cell differentiation during embryogenesis.  
In this study, I demonstrate that expression of the majority of the human HOX class I 
homeobox genes is significantly associated with clinical covariates in neuroblastoma using 
microarray expression data of 649 primary tumors. Moreover, a HOX gene expression-based 
classifier predicted neuroblastoma patient outcome independently from age, stage and MYCN 
amplification status. Among all HOX genes, HOXC9 expression was most prominently 
associated with favorable prognostic markers. Notably, elevated HOX9 expression was 
significantly associated with spontaneous regression in infant neuroblastoma.  
Re-expression of HOXC9 in three neuroblastoma cell lines led to a significant 
reduction in cell viability, and abrogated tumor growth almost completely in neuroblastoma 
xenografts. Neuroblastoma growth arrest was related to induction of programmed cell death, 
as indicated by an increase in the sub-G1 fraction and translocation of phosphatidylserine to 
the outer membrane. Programmed cell death was associated with a shifted BCL-2/BAX ratio, 
the release of cytochrome c from the mitochondria into the cytosol, and activation of the 
intrinsic cascade of caspases, indicating that HOXC9 re-expression triggers the intrinsic 
apoptotic pathway. Furthermore, re-expression of HOXC9 resulted in a significant reduction 
of proliferation accompanied by cell cycle arrest in the G0/G1 phase, and decreased colony 
formation in soft agar. Neuronal differentiation was observed in one out of three cell lines 
upon HOXC9 re-expression.  
 Summary 
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Collectively, the results of my thesis demonstrate a strong prognostic impact of HOX 
gene expression in neuroblastoma, and point towards a critical role of Hox-C9 in 
neuroblastoma spontaneous regression. 
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1. Introduction 
1.1 Neuroblastoma  
Neuroblastoma, one of the most common malignant solid tumors occurring in infancy and 
childhood, accounts for 8% of all pediatric cancers (1-3). With a median age of 22 months at 
diagnosis, neuroblastoma is responsible for 15% of all childhood cancer deaths (4). 
Neuroblastoma represents a neuro-ectodermal malignancy derived from fetal precursors of the 
sympathetic nervous system (5, 6). In the developing embryo, neuroblasts migrate along the 
neural crest, and populate primarily the sympathetic ganglia and adrenal medulla. The 
distribution pattern of these cells correlates highly with the sites of primary neuroblastomas 
and consequently neuroblastomas are most often located in the adrenal medulla or along the 
sympathetic nervous system chain ganglia. Multiple genetic abnormalities, like chromosomal 
gains and losses, aneuploidy, and amplification of chromosomal material, are found in 
neuroblastoma. Age at diagnosis, tumor stage and biological features encountered in 
neuroblastoma tumor cells are important prognostic factors and in use for risk estimation and 
treatment stratification. Neuroblastoma shows remarkable variations in clinical presentation 
ranging from aggressive, therapy-resistant progression to spontaneous regression, which 
regularly occurs in younger infants with both localized and metastasized disease. 
Furthermore, neuroblastoma cells show the potential to differentiate towards a sympathetic 
ganglion cell phenotype (9). The arrested differentiation of neuroblasts is proposed to be an 
early event in the pathogenesis of neuroblastoma caused by a disruption of the normal 
developmental genetic program (7). It has been suggested that in spontaneously regressing 
neuroblastomas this disruption results in an reversible phenotype, with initial proliferation of 
immature neural-crest cells followed by a delayed activation of naturally occurring processes 
of programmed cell death and differentiation (10-12). 
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1.1.1 International Neuroblastoma Staging System (INSS)  
Staging of neuroblastoma is performed according to the International Neuroblastoma Staging 
System (INSS, Table 1) (8). The INSS is based on clinical, radiographic and surgical criteria 
and is now widely accepted as the standard neuroblastoma staging system.  
INSS 
Stage      Definition 
1  Localized tumor with complete gross excision, with or without microscopic 
residual diseases; representative ipsilateral lymph nodes negative for tumor 
microscopically (nodes attached to and removed with the primary tumor may 
be positive). 
2A  Localized tumor with incomplete gross excision; representative ipsilateral 
nonadherent lymph nodes negative for tumor microscopically. 
2B  Localized tumor with or without complete gross excision, with ipsilateral 
nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph 
nodes must be negative microscopically. 
3 Unresectable unilateral tumor infiltrating across the midline, with or without 
regional lymph node involvement; or localized unilateral tumor with 
contralateral regional lymph node involvement; or midline tumor with bilateral 
extension by infiltration (unresectable) or by lymph node involvement.  
 The midline is defined as the vertebral column. Tumors originating on one side and acrossing 
the midline must infiltrate to or beyond the opposite side of the vertebral column.  
4 Any primary tumor with dissemination to distant lymph nodes, bone, bone 
marrow, liver, skin and/or other organs (except as defined as 4S).  
4S Localized primary tumor (as defined for stage 1, 2A or 2B), with dissemination 
limited to skin, liver, and/or bone marrow (limited to infants < 1 year of age).  
 Marrow involvement in stage 4S should be minimal, i.e., < 10% of total nucleated cells 
indentified as malignant on bone marrow biopsy or on marrow aspirate. More extensive 
marrow involvement would be considered to be stage 4. The MIBG scan (if performed) should 
be negative in marrow.  
Table 1: INSS (8). 
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The INSS distinguishes three localized stages (stage 1-3, collectively approximately 50% of 
cases) from an unfavorable, disseminated stage (stage 4, approximately 40% of cases). The 
remaining approximately 10% of patients present with a special form of disseminated disease 
categorized as stage 4S (“S”, special). Stage 4S diseases were first described by D’Angio et 
al. (9) and are clinically defined by patients younger than 12 months of age and a restrict 
pattern of distant metastases to skin, liver and bone marrow. A high percentage of stage 4S 
patients regress spontaneously or differentiate into benign ganglioneuroma (9). 
 
1.1.2 Neuroblastoma risk stratification 
Neuroblastoma risk assessment depends on several clinical and biological features. The main 
goal of neuroblastoma risk stratification is to predict each patients individual risk to die from 
the disease at diagnosis. To choose the most appropriate form of treatment, the German 
Neuroblastoma Trial NB2004 categorizes patients into three risk-based groups: low-, 
intermediate- and high-risk. The NB2004 risk stratification criteria (Figure 1, (10)) include 
clinical parameters such as tumor stage defined by INSS (8) and patient age at diagnosis, 
since younger age at diagnosis is significantly associated with better outcome (11, 12). 
Furthermore, genetic characteristics like MYCN amplification status (13) and loss of the short 
arm of chromosome 1 (14) are included as markers of poor outcome in the NB2004 risk 
stratification criteria. Further markers used in international clinical trials for neuroblastoma 
risk stratification (15) are histopathologic classification according to the Shimada system (16), 
allelic loss of chromosomal regions at 11q (14, 17) and DNA ploidy (18, 19).  
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Figure 1: Risk stratification according to the German Neuroblastoma Trial, NB2004 (10). 
 
It has been demonstrated that risk stratification according to NB2004 criteria significantly 
discriminates neuroblastoma patients with different event-free survival (EFS) and overall 
survival (OS) (Figure 2, (20)).  
 
  
Figure 2: Kaplan-Meier estimates for EFS and OS for 428 neuroblastoma patients stratified according 
to the German neuroblastoma trial NB2004 (10). Abbreviations: LR, low-risk; IR, intermediate-risk; 
HR, high-risk.  
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Despite such complex risk stratification systems, there are some neuroblastoma cases where 
the individual tumor behavior is not precisely predictable on initial presentation. It has been 
thus suggested to implement global genetic aberration patterns or gene-expression signatures 
in risk estimation systems to more accurately predict neuroblastoma patient outcome (20-26).  
 
1.1.3 Molecular biology of neuroblastoma  
Clinical heterogeneity is a hallmark of neuroblastoma which is reflected by specific patterns 
of genetic and transcriptomic abnormalities. The best characterized biological parameters 
associated with clinical phenotypes are MYCN amplification, ALK amplification and 
activating mutations, 1p and 11q deletion, unbalanced 17q gain and aberrant gene expression 
patterns. 
 
1.1.3.1 MYCN amplification 
The genetic aberration most consistently associated with advanced disease stage, rapid tumor 
progression and poor outcome in neuroblastoma, is genomic amplification of the proto-
oncogene MYCN (27-29). Amplification of MYCN in neuroblastoma was first described by 
Schwab et al. in 1983 (30). MYCN is located at chromosome 2p24, and amplification occurs 
in about 20% of all neuroblastoma cases. MYCN amplification values range between 5- to 
more than 500-fold, which lead to its overexpression at mRNA and protein level (31-35). 
High expression of MYCN in neuroblastoma results in activation of genes associated with 
aggressive tumor behavior. The exact mechanisms by which MYCN amplification contributes 
to aggressive tumor biology are still not clarified. The transcription factor N-myc regulates a 
huge amount of target genes, including transcriptional regulators (36). Many of these genes 
are involved in development and neuronal differentiation (36), cell proliferation (37), cell 
cycle (38) and apoptosis (36). However, even though MYCN amplification is strongly 
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associated with high-risk neuroblastomas, more than 60% of patients with aggressive disease 
do not harbor this amplification. 
 
1.1.3.2 ALK amplification and activating mutations 
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase 
preferentially expressed in the central and peripheral nervous system (39). Activating 
mutations in the tyrosine kinase domain of ALK encode for single base substitutions in key 
regions of the enzymatic domain and result in constitutive activation of the kinase and a 
premalignant state. These mutations appear to be responsible for most of the rare cases of 
hereditary neuroblastomas, and might also be relevant for a smaller fraction of sporadic 
neuroblastomas (6-9%). A substantial number of primary neuroblastomas (20-25%) present 
low-level copy number gains at the ALK locus on 2p23 (40-42). High-level genomic 
amplification of ALK occurs in about 1% of neuroblastoma, and is highly associated with 
MYCN amplification (43-46).  
 
1.1.3.3 Chromosome 1p deletion 
Chromosome 1p36 deletion is a common structural aberration occurring in about 30% of all 
neuroblastomas. The deletion is variable but consistently encompasses 1p36.1 to 1pter, 
including a 261 kb region at 1p36.3, which is highly correlated with the amplification of 
MYCN and advanced diseases stage (47-51). Further, 1p36 deletion is an independent 
predictor of neuroblastoma progression, and evidence suggests that 1p36 deletion predicts an 
increased risk of relapse in patients with localized tumors (47-51). Several lines of evidence 
have led to the hypothesis that this region harbors tumor suppressor genes involved in the 
development of neuroblastoma. Consequently, several candidate genes were found to be 
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decreased in expression levels. However, none of these have been proven to be crucial for the 
pathogenesis of aggressive neuroblastoma (52-55).  
 
1.1.3.4 Chromosome 11q deletion 
Allelic loss of 11q occurs in a subgroup of high-risk neuroblastomas accounting for 
approximately 15-22% of all patients (56-58). The majority of 11q deletions are distal losses 
encompassing a large portion of the long arm of chromosome 11. Aberrations at 11q are 
rarely seen in tumors with MYCN amplification, but they remain highly associated with other 
high-risk features like stage 4 disease, increased age at diagnosis and poor EFS and OS (17, 
59). Consequently, the presence of 11q deletions and MYCN amplifications appear to 
delineate two molecularly distinct subgroups of unfavorable neuroblastoma.  
 
1.1.3.5 Chromosome 17q gain 
Unbalanced gain of a long segment at chromosome 17q is found in 54-68% of neuroblastoma 
patients, thus representing the most frequent structural genomic aberration in neuroblastoma 
(60-62). Although 17q gains are associated with poor outcome and hence with unfavorable 
prognostic markers such as stage 4 disease, increased age at diagnosis and other chromosomal 
aberrations such as MYCN amplification, 1p and 11q loss, the pertinence of 17q gain as an 
independent prognostic marker for neuroblastoma patient outcome has remained controversial 
(60, 62). 
 
1.1.3.6 DNA index  
DNA ploidy is a well established prognostic marker in several human malignancies, and an 
aneuploid (hyperdiploid or near-triploid) DNA content is usually an indicator for disease 
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progression and poor outcome. In 1984, Look et al. (19) showed that neuroblastoma 
represents an exception since aneuploid neuroblastomas are correlated with favorable 
outcome and a better response to chemotherapy, particular in younger patients (< 12 months). 
For neuroblastoma patients older than 1-2 years of age, DNA ploidy loses its prognostic 
significance (63).  
 
1.1.3.7 Aberrant gene expression 
In addition to genomic aberrations, alterations in gene expression have been studied 
extensively in neuroblastoma (10, 20, 25, 64). Of particular interest are members of the 
neurotrophin receptor pathways, since the neurotrophin receptors TrkA, TrkB and TrkC 
together with their ligands NGF, BDNF and NT3 are important regulators of survival, growth, 
and differentiation of neuronal cells (7). The first report showing elevated TrkA expression in 
favorable neuroblastomas was presented by Nakagawara and colleagues in 1993 (7). High 
TrkA expression is associated with favorable prognostic markers and favorable outcome, 
whereas decreased expression correlates strongly with poor prognosis and MYCN 
amplification (7, 65). Another candidate gene in neuroblastoma is caspase 8, an apoptosis-
related cysteine peptidase. Loss of caspase 8 expression is estimated to occur in 25-35% of 
neuroblastoma patients, predominantly high-risk tumors. Absence of caspase 8 expression 
appears to be strongly correlated with MYCN amplification (66, 67). Caspase 8 is 
homozygously deleted in a small subset of neuroblastomas (67), but more importantly, it is 
inactivated by hypermethylation in nearly all neuroblastoma patients with MYCN 
amplification (67). Loss of caspase 8 expression may represent a critical event for impaired 
activation of the extrinsic apoptotic pathway in high-risk neuroblastoma.  
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1.1.4 Hereditary neuroblastoma 
Familial neuroblastoma accounts for 1-2% of all neuroblastomas (68) and are associated with 
younger age at diagnosis and multiple sites of primary tumors. Apart from that, hereditary 
neuroblastoma shows the same diverse clinical behavior as sporadic neuroblastomas, ranging 
from aggressive progression to spontaneous regression (69). Germline mutations in two 
genes, PHOX2B and ALK, account for around 90% of hereditary neuroblastomas. PHOX2B 
belongs to the homeobox gene family and is involved in the development of the normal 
autonomic nervous system (70, 71). Loss of function mutations in PHOX2B have been found 
in a small subset of hereditary neuroblastomas and rarely in sporadic neuroblastomas (72). 
ALK mutations (see also section 1.1.3.2) are known to be the most common cause of 
hereditary neuroblastoma so far (42).  
 
1.1.5 Origin of neuroblastoma  
The neural crest develops early in embryogenesis (73) and consists of pluripotent cells that 
migrate from the neural tube to the dorsal aorta. At this early stage of neural crest cell 
migration and differentiation, bone morphogenetic protein (BMP) signaling plays an 
important role for cell fate determination and specification (74). From the dorsal aorta, 
pluripotent cells migrate further to sites where they differentiate into several lineages, 
including the sympathoadrenal lineage. The oncogenic events responsible for neuroblastoma 
development appear to be strictly lineage-dependent, because neuroblastomas never arise 
from other neural precursors than sympathoadrenal lineage cells (75). The cell fate 
specification is then regulated by multiple transcription factors and their target genes which 
includes several growth factors and growth factor receptors (76, 77). Homeodomain 
containing genes such as ASCL1 (78, 79), PHOX2A (80, 81), PHOX2B (82) and HAND2 (83, 
84) appear to be of high impotance for cell fate determination and sympathetic differentiation. 
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For example, ASCL1 expression usually decreases after transient expression during the 
development of neural crest cells, which in turn promotes differentiation to mature 
sympathetic neurons (85), whereas high expression of ASCL1 is still detectable in 
neuroblastomas (86, 87). The transcription factors Phox2a and Phox2b are essential for the 
differentiation of noradrenergic neurons (88). PHOX2A and PHOX2B encode two highly 
related homeobox transcription factors with similar expression patterns throughout the 
peripheral autonomic nervous system development (89). Although rare, PHOX2B mutations 
were found in hereditary and sporadic neuroblastomas as indicated in section 1.1.4. PHOX2B 
was identified as the major disease causing gene of congenital central hypoventilation 
syndrome (CCHS) (70), and CCHS patients are predisposed to develop tumors of the 
sympathetic nervous system, such as neuroblastoma (90). PHOX2B also regulates, among 
other factors, the expression of HAND2 (83), another candidate tumor suppressor gene, which 
is de-regulated in neuroblastoma (84). Together with MYCN, these factors control neural crest 
cell fate and are necessary for sympathetic neuronal differentiation. As MYCN is frequently 
amplified in neuroblastoma, it has been suggested that its de-regulation may play a major role 
in the cellular transformation process and thus the initiation of neuroblastoma at this stage of 
cell maturation (83). Finally, the terminal differentiation of sympathetic progenitor neurons 
depends on TrkC and TrkA receptor stimulation by the neurotrophins NT3 and NGF. 
Increased expression of TRKC and activation by NT3 induces up-regulation of TRKA. 
Activation of the TrkA receptor by NGF’s then leads to the terminal differentiation of 
sympathetic nerve cells. Consistent with these regulatory functions, a higher expression of 
TRKA and TRKC was found to be strongly correlated with favorable neuroblastomas (7, 91). 
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Figure 3: Regulators of the sympathetic nervous system cell lineage (Figure modified from Mohlin et 
al. (83)). BMP signaling initiates the migration of neural crest (NC) cells and commits precursor cells 
to melanocytic, glial and sympathetic neuronal lineages. The main cell types of the sympathetic 
nervous system (SNS) are proposed to originate from sympathoadrenal (SA) progenitor cells. Cell fate 
restriction is induced and controlled by a set of transcription factors (Ascl1, Phox2a Phox2b and 
Hand2) expressed at various stages of development. MYCN gene expression is first detectable after 
cell fate restriction has been induced, and it is suggested that MYCN amplified tumors arise at this 
developmental stage. Based on a strong correlation of high TRKA expression levels with more 
favorable neuroblastomas (NB), ganglioneuroblastomas (GNB) and ganglioneuromas (GN), it is 
supposed that high TRKA expression is sufficient to induce further differentiation even if the cells are 
already neoplastic. 
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1.1.6 Spontaneous regression and differentiation in neuroblastoma  
Spontaneous regression of neuroblastoma was first reported by Beckwith and Perrin in 1963 
(92). In infants, the vast majority of neuroblastomas may disappear before becoming 
clinically apparent, as suggested by several mass screening studies on infants, in which a 
significant increase of neuroblastoma cases was detected, while a decrease in the frequency of 
advanced disease stages in older children was not observed (93-96). These investigations have 
led to the assumption that a large number of neuroblastomas detected by mass screening are 
favorable tumors that regress spontaneously.  
In general, spontaneous regression and differentiation of neuroblastomas are observed 
less frequently in older patients (21, 97). It has been suggested that the physiologic genetic 
program of neuroblast differentiation and growth control (Figure 3) is disrupted in 
neuroblastoma (7), and that this developmental arrest may be reversible and activated delayed 
in spontaneously regressing neuroblastoms. In this context, a delayed activation of naturally 
occurring processes of programmed cell death and neuronal differentiation has been suspected 
(98-100). Consistent with its embryonic nature, many genes de-regulated in neuroblastoma 
are involved in developmental processes (75). Among these, several transcription factors 
involved in the development of autonomic neural crest derivates (Figure 3) are implicated in 
the pathogenesis of neuroblastoma (30, 71, 82, 83, 101), and various HOX genes have been 
described to be aberrantly expressed in neuroblastoma cell lines and primary tumors (Table 2, 
(36, 102)).  
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1.2 Homeobox genes  
HOX genes are master regulators of embryonic development and stem cell differentiation. 
They encode for highly conserved transcription factors that organize the anterior-posterior 
(AP) body axis during embryogenesis (103). Beside this, they act as critical regulators of 
growth and differentiation. They control cell identity, cellular communication, cell cycle 
progression, hematopoiesis, and apoptosis (104) by activating or repressing their target genes 
(105-109). HOX genes are separated in 2 classes; class I clustered HOX genes and class II 
dispersed HOX genes (110). The mammalian class I HOX gene cluster comprises 39 HOX 
genes, which are arranged within 4 different clusters (A – D) on 4 different chromosomes 
(chromosome 2, 7, 12, and 17) and organized into 13 paralogous groups.  
 
 
 
 Introduction 
 
 14 
 
 
Figure 4: Homeotic gene organization and transcriptional expression (Figure modified from Nolte and 
Krumlauf (111)). In humans, there are 4 clusters on 4 chromosomes with 39 HOX genes in total. 
Genes located closer to the 3’ end of the cluster are stronger expressed in anterior tissues whereas 5’ 
located genes show a stronger expression pattern in posterior tissues (spatial colinearity). HOX genes 
that are positioned more 5’ in the cluster (yellow) will have a dominant phenotype compared with 
those more 3’ (green), which is described as posterior prevalence. HOX genes are expressed 
temporally in an order corresponding to their positions from 3’ to 5’ within each cluster, known as 
temporal colinearity. Early 3’ located HOX genes display the highest level of retinoic acid (RA) 
responsiveness, whereas the 5’ members show stronger response to fibroblast growth factors (FGF’s). 
 
1.2.1 HOX gene expression  
HOX gene expression is well controlled during embryonic development. The position of a 
HOX gene from 3’ to 5’ within a HOX cluster corresponds to its expression along the AP axis 
of the body and to its temporally order of expression (spatial and temporal colinearity). HOX 
genes located at the 3’ region of each HOX cluster are activated earlier and more anteriorly 
compared to the more 5’ genes which are expressed later and more posterior (112, 113). 
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Furthermore, HOX genes which are located in the 5’ region of the HOX cluster lead to a more 
dominant phenotype than those located more 3’ (posterior prevalence). This precisely 
organized expression pattern is modulated by complex regulative mechanisms.  
It has been suggested that a unidirectional chromatin opening process plays a role in 
the spatial and temporal expression pattern of HOX genes (114). Two classes of chromatin-
modifying proteins epigenetically regulate HOX gene expression. The Polycomb group (PcG) 
proteins and trithorax group (TrxG) proteins form multiprotein chromatin remodeling 
complexes that either repress (PcG) or activate (TrxG) the transcription of HOX genes.  
Furthermore, HOX gene expression is controlled by a dose dependent response to 
retinoic acid (RA) and fibroblast growth factors (FGF’s) (115-117). HOX genes located more 
3’ in the HOX cluster show a stronger response to RA as compared to 5’ located HOX genes, 
which are more sensitive to FGF’s (118, 119). Although RA and FGF’s are the best described 
and analyzed global regulators of HOX gene expression, there are several other factors that 
can influence HOX gene expression such as regulative RNA’s (miRNA’s (120), lincRNA’s 
(121, 122) or HOTAIR’s (123)). Finally, HOX gene expression is also regulated by auto- and 
cross-regulative processes (124-126), in which Hox transcription factors bind to HOX 
responsive elements (HRE’s) together with one or more cofactors. HRE mediated HOX 
regulation functions in three different ways: Hox transcription factors can regulate their own 
expression (auto-regulation), they can activate the expression of other HOX genes within the 
same segment (cross-activation), or they can have antagonistic interactions in which one Hox 
transcription factor represses the expression of another HOX gene (cross-repression).    
 
1.2.2 Hox cofactors  
Hox cofactors are important for modifying Hox DNA binding sensitivity and specificity 
(127). Although Hox proteins can bind sequence-specific to a 4-base pair target site (TAAT) 
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as single molecule, their affinity to this site is low in general due to the very short sequence, 
which allows only restricted specificity in target selection. HRE’s are essential for Hox target 
regulation. In addition to Hox binding sites, they also contain specific binding sites for Hox 
cofactors. Therefore, the transcriptional regulation by Hox and cofactor complexes is more 
specific and allows a precisely defined transcriptional regulation of target genes. Pbx (128-
131) and Meis (132, 133) are the two best studied cofactors of Hox proteins, both belonging 
to the TALE (three-amino acid-loop-extension) family of homeodomain proteins, which are 
known to be involved in various forms of leukemia (134). Interestingly, both MEIS and PBX 
have been described to be involved in the pathogenesis of neuroblastoma (135).  
 
1.2.3 HOX genes in human diseases 
De-regulated expression of HOX genes leads to various forms of human disease (114). HOX 
genes are involved in several disorders of limb development. Muragaki and colleagues 
showed that mutation of HOXD13 cause synpolydactyly in humans (136). HOXA13, another 
member of the class I HOX gene family, was identified to play a potential role in the 
pathogenesis of hand/foot/genital syndrome (137, 138). A malformation of the foot, 
congenital vertical talus, has been associated to a HOXD10 mutation (139), and it has been 
hypothesized that HOX genes may be involved in clubfoot and other limb malformations 
(140, 141). In the central nervous system, homozygous HOXA1 mutations disrupt human 
brainstem, inner ear, cardiovascular and cognitive development (142).  
 
1.2.3.1 HOX genes in cancer 
De-regulated expression of HOX genes is reported in several tumor entities (Table 2). Precise 
mechanisms by which HOX genes mediate tumor formation or tumor suppression are still not 
defined. They may influence tumorigenity through proliferative, apoptotic or angiogenic 
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effects, but the activity is dependent on the availability of their cofactors (143, 144). Aberrant 
expression of a single HOX gene can lead to tumor formation in one type of tissue by 
blocking cell differentiation or apoptosis and increasing proliferation, whereas the same HOX 
gene can exert tumor suppressive functions in a different tissue type. HOXB13, for example, 
represents a tumor suppressor gene (145) and is necessary for normal prostate development 
(146) while it is associated with tumorigenesis and aggressive disease course in breast cancer 
(147). This tissue specificity is also reflected in the broad variation of signaling pathways by 
which HOX genes exert their effects. In neuroblastoma, the expression of a single HOX gene 
(HOXC6) induces differentiation and prevents tumorigenesis (148), while in other diseases 
such as acute myeloid leukemia (AML), overexpression of HOXC6 promotes clonal 
expansion (149). An example for a fusion protein-mediated malignant transformation is given 
by HOXA9, which is overexpressed and fused to NUP98 and represents the gene most highly 
correlated with poor prognosis (150, 151) and treatment failure in AML (152).  
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Tumor Entity HOX Gene Expression Effect 
Esophageal 
squamous cell 
carcinoma 
5’ HOX genes Increased Associated with primary tumors (153) 
Lung 
Carcinoma 
5’ HOXA and HOXD 
genes, A1,C5 
Increased Associated with primary tumors (154) 
A7, A9 Decreased 
(promoter 
methylation) 
Associated with primary tumors (155) 
Neuroblastoma 
D1, D8, C6 Decreased Expressed in differentiated cell lines (156) 
C6, C11 Decreased Expression leads to cell differentiation 
(148) 
Ovarian 
Carcinoma 
B13 Increased  Promotes cancer progression (157) 
B4 Increased Associated with primary tumors and cell 
lines (158) 
Cervical 
Carcinoma 
C Cluster Increased Associated with primary tumors (159) 
C10 Increased Increased invasion (160) 
Prostate 
Carcinoma 
B13 Decreased Loss of differentiation, transactivation of 
androgen receptors and proliferation (145, 
146, 161) 
C8 Increased Associated with primary tumors, loss of 
differentiation, androgen receptor -
independent growth (162) 
Breast 
Carcinoma 
A5 Decreased 
(promoter 
methylation)  
Down-regulation of p53, decreased 
apoptosis (163-165) 
A10 Decreased Down-regulation of p53 (166) 
B7 Increased Up-regulation of FGF2, associated with 
bone metastases, increased invasion and 
vascularization, Associated with HER2 
amplification (167-169) 
B13 Increased Associated with tamoxifen resistance in 
tumors, increased migration and invasion 
in vitro (147, 170, 171) 
Leukemia 
A9, A10, C6 Increased Associated with aggressive ALL (172) 
A9 Increased Increased proliferation by NUP98-HOXA9 
fusion, MEIS1 and FLT3 up-regulation 
(152, 173-175) 
Astrocytoma 
A6, A7, A9, A13, B13, 
D4, D9, D10, D13 
Increased Associated with primary tumors and cell 
lines (110) 
Colorectal Cancer B13 Decreased 
Associated with primary tumors and cell 
lines, down-regulates the β-catenin-TCF 
pathway  Inhibition of cell proliferation 
(176) 
Renal Carcinoma 
B5, B9 Decreased Associated with primary tumors (177) 
C11 Increased Associated with primary tumors (177) 
Pediatric low-grade 
gliomas 
D1, D12 Increased Associated with primary tumors (178) 
D3 Decreased Associated with primary tumors (178) 
 
Table 2: HOX genes in tumorigenesis (Table modified from Abate-Shen (104), Shah and Sukum 
(179)). Abbreviation: ALL, acute lymphocytic leukaemia.  
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1.2.3.2 HOX genes in neuroblastoma 
Differentiation of neuroblastoma cell lines and primary tumors can be induced by various 
agents (180) including RA (181). Spontaneous differentiation in infant neuroblastoma into 
less aggressive ganglioneuroblastoma or benign ganglioneuroma was first described by 
Cushing in 1927 (182), and occurs regularly (183). In 1990, Peverali and colleagues showed 
that morphological maturation of neuroblastoma cell lines toward a neuronal differentiation 
phenotype is associated with increased HOX gene expression (184). Manohar and colleagues 
(102, 156) further demonstrated that HOX genes, such as HOXC6, HOXD1 and HOXD8, are 
expressed at a low level in neuroblastoma cell lines, which can be increased by RA treatment. 
Zhang et al. (148) showed that neuroblastoma GOTO cells differentiate into schwannian cell 
types when exposed to 5-bromo-2’-deoxyuridine (BrdU) (148), which is accompanied with 
increased expression of HOXC6, HOXC11 and S100B, a schwannian cell marker gene. They 
further demonstrated that these HOX genes directly bind to the S100B promoter and hence 
lead to its up-regulation.  
Genes involved in development or neural differentiation have been described to be de-
regulated in MYCN amplified neuroblastomas, indicating that overexpression of MYCN is 
associated with altered maturation of neuroblastoma progenitor cells. As an example, 
Alaminos et al. showed that, among other developmental regulators, the expression of 
HOXC10 is decreased in MYCN amplified primary neuroblastoma tumors (36). In a recent 
publication, Zha and coworkers demonstrated that increased expression of HOXD8, HOXD9 
and HOXD10 results in growth arrest and neuronal differentiation in SK-N-BE(2)-C 
neuroblastoma cells (185). 
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1.2.4 HOXC9 gene expression in development and tumorigenesis 
The molecular mechanisms by which HOXC9 regulates the transcription of its target genes as 
well as the direct targets themselves are widely unknown. A role for HOXC9 as a master 
regulator of motor neuron organization and development was proposed recently by Jung and 
colleagues who demonstrated that HOXC9 exerts its regulative function through global cross-
repressive activities (186). In fetal human smooth muscle cells (SMC), HOXC9 was found to 
be expressed at higher levels as compared to adult SMC’s, which indicates its role in 
specifying the fetal SMC phenotype (187). Furtheremore, it has been hypothesized that 
HOXC9 is involved in the process of cell differentiation of bone marrow derived stem cells to 
endothelial cells (188). HOXC9 expression was detected in hind limb blood vessels of mice 
(189) and the axial vasculature of zebrafish (190). Moreover, strong HOXC9 expression was 
found in human umbilical vein endothelial cell (HUVEC) spheroids which are characterized 
by tight cell contacts and resting proliferation (191). Enhanced expression of HOXC9 leads to 
the inhibition of major angiogenic processes like tube formation, migration and proliferation 
in human vascular endothelial cells as demonstrated by Stoll et al. (192). They further showed 
that HOXC9 exerts its anti-angiogenic function by repressing the transcription of interleukin 
8, and independent of the VEGF pathway.  
Evidence for Hox-C9 acting as a “tumor suppressor” is given by Kikuyama and co-
workers (193) who showed that the HOXC9 promoter is frequently methylated in primary 
breast cancers. HOXC9 promoter methylation was also observed in stage I non-small-cell lung 
carcinoma samples, whereas it was absent in the lung tissue of non-cancerous lesions (194). 
Recently, high HOXC9 expression was found to be associated with neuroblastoma cell 
differentiation and decreased cell proliferation (195). In contrast to its tumor suppressive 
functions, HOXC9 may also stimulate tumor formation and malignancy and thus act as a 
potential “oncogene”. In cervical cancer, for example, HOXC9 was reported to be expressed 
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in tumors but not in non-neoplastic tissue (196). It has been hypothesized that the expression 
of HOXC9 is not implicated in the physiology of normal cervix, but it is necessary for 
carcinogenesis in this tumor entity. Likewise, normal brain tissues lack HOXC9 expression, 
while its expression is detectable in astrocytomas of different grades, and HOXC9 expression 
levels are strongly associated with the grade of malignancy (197). A transgenic mouse model 
lacking HOXC9 was established and described in 1995 by Suemori and colleagues (198). The 
HOXC9 knock-out mouse displayed anterior transformation of the vertebrae and 
malformation of the sternum and ribs (198), however, this model has not yet been used for 
investigating the role of HOXC9 in cancer biology.  
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2  Aim of the study 
Neuroblastoma is an embryonal tumor derived from fetal precursors of the sympathetic 
nervous system, and has the highest frequency of spontaneous regression observed in human 
malignancies. It has been suggested that spontaneous regression may represent a delayed 
activation of developmental apoptotic pathways. However, the molecular mechanisms of this 
peculiar phenomenon have remained enigmatic. Understanding the molecular processes 
underlying spontaneous regression is therefore a major challenge in neuroblastoma research.  
Since expression of HOX transcription factor genes is tightly regulated during 
embryogenesis and fundamental for a normal embryonic development, I suggested a role of 
these genes in neuroblastoma pathogenesis in general and in spontaneous regression in 
particular. Using microarray-based expression data of a large cohort (n= 649) of primary 
neuroblastomas, I aimed at determining the gene expression patterns of class I HOX genes and 
their association with clinical phenotypes. HOXC9 was found to be strongly associated with 
favorable prognostic markers, beneficial outcome and spontaneous regression in primary 
neuroblastoma. I therefore aimed to determine the functional role of Hox-C9 in 
neuroblastoma pathogenesis and spontaneous regression by generating and analyzing 
HOXC9-transgenic neuroblastoma cell lines.    
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3  Materials and Methods 
3.1 Microarrays and data analysis 
3.1.1 Neuroblastoma patient characteristics 
Tumors of 649 neuroblastoma patients were analyzed. Neuroblastoma tumor stage was 
classified according to the International Neuroblastoma Staging System (8): stage 1, n= 153; 
stage 2, n= 113; stage 3, n= 91; stage 4, n= 214; stage 4S, n= 78. Patients age at diagnosis 
ranged from 0 to 25.4 years (median age, 1.1 years). MYCN amplification was observed in 93 
tumors, while it was absent in 550 tumors (not determined, n= 6). Loss of chromosome 1p 
were observed in 140 tumors, while the group of patients with normal chromosome 1p status 
comprised 407 (not determined, n= 102). Neuroblastoma tumors were further classified 
according to a prognostic gene expression-based classifier (25): favorable, n= 231; 
unfavorable n= 184; unclassified, n= 234. Primary tumors were localized in the abdomen 
(n= 135), at the neck/chest (n= 69) or the adrenal glands (n= 276). The primary tumor 
localization for the remaining 169 patients was unknown. Median follow-up for patients 
without fatal events was 6.4 years (range, 0.2-18.1 years). The subgroup of patients showing 
regression of neuroblastoma consisted of 43 infants (localized, n= 14; stage 4S, n= 29), in 
which the tumor manifestations showed unambiguous regression without any cytotoxic 
treatment (199). The neuroblastoma subgroups used for methylation and array-based 
Comparative Genomic Hybridization (aCGH) analysis consisted of 46 and 209 tumors, 
respectively. Risk group assignment of corresponding patients was performed according to 
the International Neuroblastoma Risk Group (INRG) classification system (15) (methylation, 
high-risk, n= 21; intermediate- and low-risk, n= 24; unclassified, n= 1; aCGH, high-risk, 
n= 56; intermediate- and low-risk, n= 153).  
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3.1.2 Gene expression arrays 
Single-color gene expression profiles from 649 neuroblastoma tumors were generated 
previously in the laboratory of Prof. Dr. Matthias Fischer using customized 4 x 44K 60-mer 
oligonucleotide microarrays produced by Agilent Technologies (Palo Alto, CA, USA). These 
microarrays included all probes represented by Agilent’s Whole Human Genome Oligo 
Microarray and all probes of the version V2.0 of the 2 x 11K customized microarray that were 
not present in the former probe set (25). Annotation files are available through the Gene 
Expression Omnibus database (Accession ID: GSE45480). Single-color gene expression 
profiles of neuroblastoma cell lines were generated using the same array platform. Total RNA 
of HOXC9 and GFP-expressing SK-N-AS and IMR-32 neuroblastoma cells were isolated at 
0, 6, 12, 24, 48 and 96 h using TRIZOL reagent (Invitrogen, Karlsruhe, Germany). Integrity 
of the isolated RNA was assessed using the 2100 Bioanalyzer (Agilent Technologies), and 
only samples with an RNA integrity number (RIN) of at least 7.5 were considered for further 
processing. For labeling and hybridization, 1 μg of RNA was linearly amplified and labeled 
with Cy3 using Agilent’s one-color Quick Amp Labeling Kit (Agilent Technologies) 
following the instructions of the manufacturer’s protocol. Then, 1650 ng of Cy3-labeled 
cRNA was hybridized to the 4 x 44K arrays using Agilent’s High-RPM Gene Expression Hyb 
Kit (Agilent Technologies) according to the manufacturer’s protocol. Hybridization was 
performed for 17 h at 65 °C in a rotating hybridization oven (Robbins Scientific, CA, USA) at 
10 rpm according to the company’s recommendations. After washing and scanning, resulting 
TIFF images were processed using Agilent’s Feature Extraction software Version 9.5.1 
(Agilent Technologies). The quantile normalization method (200) was applied on gene 
expression raw data. All raw and normalized microarray data are available through the Gene 
Expression Omnibus database (Accession: GSE45480).  
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3.1.2.1 Analysis of gene expression data 
Associations between class I HOX mRNA expression levels and neuroblastoma subgroups, 
prognostic markers and patient outcome were analyzed using single-color gene expression 
profiles from 649 neuroblastoma tumors. All HOX genes were first tested in a univariable Cox 
regression model based on OS and EFS. For all HOX genes with p-values ≤ 0.05 the whole 
cohort (n= 649) was divided into quartiles based on HOX gene expression levels. Kaplan-
Meier estimates for OS (n= 649) and EFS (n= 628) were compared by log- rank test. In 
addition, HOXC9 was investigated separately. The entire set was divided into a training 
(n= 244) and validation cohort (n=405). The training cohort was divided into quartiels based 
on HOXC9 expression levels and these values were applied on the validation cohort as a cut-
off for high, intermediate-high, intermediate-low and low HOXC9 expression. Kaplan-Meier 
estimates for OS (n= 405) and EFS (n= 384) were compared by log-rank test. Recurrence, 
progression and death from disease were considered as events. Multivariate Cox proportional 
hazard models based on EFS and OS were used to analyze the prognostic impact of HOXC9 
expression in neuroblastoma. The factors age (> 18 months vs. < 18 months), tumor stage 
(stage 4 vs. stage 1-3 and 4S), MYCN amplification status (amplified vs. normal) and HOXC9 
expression were fitted into a stepwise-backward selection model.  
 
3.1.2.2 HOX gene expression-based classification 
To develop a HOX gene expression-based classifier (HOX classifier), the nearest shrunken 
centroids method (PAM) (201) was applied on HOX gene expression data from 75 
neuroblastoma patients with maximal divergent clinical outcome (patients who had died of 
disease despite cytotoxic treatment (n= 22) or survived event free more than 1000 days after 
diagnosis without cytotoxic treatment (n= 53) (25)). The classification performance in the 
training set was evaluated by a 10 times repeated 5-fold cross-validation. Probes that were 
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included in at least 65% of all cross-validation models were selected as classifier probes as 
recommended by Li et al. (202). Classification accuracy of the final HOX classifier was 
assessed in an independent validation set of 574 neuroblastoma patients using the Support 
Vector Machine (SVM) (203) algorithm. Multivariate Cox proportional hazard models based 
on EFS and OS were used to analyze the prognostic impact of this classifier. The factors age 
(< 18 months vs. > 18 months), tumor stage (stage 1-3 and 4S vs. stage 4), MYCN 
amplification status (normal vs. amplified) and HOX classifier were fitted into a stepwise-
backward selection model.  
 
3.1.2.3 Gene Ontology enrichment analyses 
To determine global differences in the expression profiles of HOXC9 and GFP-induced 
SK-N-AS and IMR-32 cells, mean expression levels of each gene between HOXC9 induced 
and control cells were compared. Differentially expressed genes, either up- or down-regulated 
after HOXC9 re-expression, were determined by applying a fold-change cut off and unpaired, 
two-tailed Students t-test. Genes with a fold-change of ≥ 2 and p-values ≤ 0.05 were 
considered as significantly differentially regulated in these groups. Gene Ontology Tree 
Machine (GOTM) (204) was used to identify functional categories associated with the 
characteristics of the respective cell line. The p-value assigned to the overrepresentation of a 
specific category was calculated by a hypergeometric test, and results were corrected for 
multiple testing (Benjamini-Hochberg).  
 
3.1.3 Array-based Comparative Genomic Hybridization  
High-resolution oligonucleotide aCGH profiles of 209 neuroblastoma tumors were generated 
previously (205, 206) using 44 K, 105 K or 1 M microarrays (Agilent Technologies). Array-
CGH analysis was preformed as described previously (206). The circular binary segmentation 
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algorithm (207) was applied to allow visualization of the resulting aCGH data by the 
Integrative Genomics Viewer (IGV) (208). Due to technical reasons, 9 out of 209 aCGH 
profiles could not be visualized. To evaluate whether chromosomal aberrations on 
chromosome 12 are associated with de-regulated HOXC9 expression, I compared the results 
with corresponding microarray gene expression data of the same tumors using two-tailed 
nonparametric tests (Kruskal-Wallis).  
 
3.2 Statistics 
Statistical analysis of associations between HOX mRNA expression levels and neuroblastoma 
subgroups, prognostic markers and outcome was performed using SPSS version 20.0 (IBM). 
Two-tailed nonparametric tests (Mann-Whitney U, and Kruskal-Wallis test) were used where 
appropriate. Kaplan-Meier estimates for OS and EFS were compared by log-rank test. 
Multivariate Cox proportional hazard models based on EFS and OS were used to analyze the 
prognostic impact of HOXC9 expression in neuroblastoma. The likelihood ratio test p for 
inclusion was ≤ 0.05 and for exclusion was > 0.05. Quantitative data for functional analyses 
were shown as means ± SD. Unpaired two-tailed Students t-tests were used where 
appropriate. 
 
3.3 Cell Culture 
SK-N-AS and CHP-212 cells were obtained from the American Tissue Culture Collection 
(ATCC, Manassas, VA, USA), IMR-32 cells were purchased from the German Collection of 
Microorganisms
 
and Cell Cultures (DSMZ, Braunschweig, Germany). Neuroblastoma cell 
lines were authenticated at the DSMZ. Neuroblastoma cell lines were maintained in RPMI-
1640 (PAA, Coelbe, Germany) supplemented with 10% fetal calf serum (FCS, PAA). 
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Inducible cell lines were maintained in RPMI-1640 supplemented with 10% Tet-free FCS 
(PAA), 50 µg/ml G418 (PAA) and 30 µg/ml Hygromycin B (PAA). PT67 packaging cells 
were obtained from Clontech Laboratories (Clontech Laboratories, Inc., Heidelberg, 
Germany) and grown in DMEM (PAA) supplemented with 10% FCS. Cells were maintained 
in a humidified incubator at 37 °C with 5% CO2 and passaged at 90% confluence using 
Trypsin-EDTA (PAA). Doxycycline (Sigma-Aldrich, Taufkirchen, Germany) was used to 
induce transgene expression (2 µg/ml). Neuroblastoma cell lines were shown to be free of 
mycoplasma by using the Venor® GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, 
Germany) according to the manufacturer’s protocol. 
 
3.3.1 Neuroblastoma cell line characteristics 
To mirror the broad spectrum of neuroblastoma disease, I selected a heterogeneous set of 
neuroblastoma cell lines for functional studies. Only cell lines which showed loss of HOXC9 
expression were considered for re-expression analyses. 
 
Cell Line Primary 
Site 
1p 
Status 
MYCN 
Status 
Tumorigenic AIG 
Potential 
Diff 
Potential 
SK-N-AS (209) adrenal del non 
amplified 
 
yes yes no 
IMR-32 (210) abdomen del amplified 
 
yes yes yes 
CHP-212 (211) kidney norm amplified 
 
no no no 
 
Table 3: Neuroblastoma cell line characteristics. Abbreviations: del., deletion; norm, normal; AIG, 
anchorage independent growth; Diff, differentiation.  
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3.3.2 Stable inducible neuroblastoma cell lines 
Polyclonal neuroblastoma cell lines stably expressing either HOXC9 or GFP under the control 
of the reverse tetracycline-controlled transactivator (rtTA) were generated using the RevTet
TM 
System (Clontech) according to the manufacturer’s instructions with marginal modifications. 
Transduction was carried out using 4 µg/ml Polybrene (Sigma-Aldrich). Transduced cells 
were selected with Hygromycin B (100 µg/ml) and Geneticin sulfate G418 (150 mg/ml) for 7 
days, expanded and assayed for HOXC9 and GFP expression upon doxycycline treatment 
using western blotting and fluorescence microscopy.  
 
3.3.3 In vitro growth properties 
3.3.3.1 Trypan blue dye exclusion  
The effect of HOXC9 expression on cell proliferation was assessed using the trypan blue dye 
exclusion test. Neuroblastoma cells were seeded in 6-well plates at a density of 2 x 
10
4
 cells/well in 2 ml RPMI-1640 (10% Tet-free FCS, 2 µg/ml doxycycline). To assure 
continuous supply of nutrients throughout the measurement interval, 1 ml fresh RPMI-1640 (2 
µg/ml doxycycline) per well were added on day 4. Cells were harvested at days 2, 4, 6 and 8 
and evaluated for number and viability by trypan blue exclusion using a hemocytometer (C-
Chip DHC-N01; Digital Bio Technology Co., LTD, Korea). 
 
3.3.3.2 Cell cycle distribution 
The influence of HOXC9 expression on cell cycle distribution was investigated by 
fluorescence-activated cell sorting (FACS) analysis. Flow cytometric analyses were 
performed using a PAS II flow cytometer (Partec, Muenster, Germany) equipped with a 
mercury vapor lamp 100 W and a filter combination for 2,4-diamidino-2-phenylindole 
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(DAPI) stained single cells. Neuroblastoma cells were seeded in 10 cm cell culture dishes at a 
density of 1 x 10
6
 cells/dish in 8 ml RPMI-1640 (10% Tet-free FCS, 2 µg/ml doxycycline). 
To ensure continuous supply of nutrients throughout the measurement interval, 4 ml fresh 
RPMI-1640 (2 µg/ml doxycycline) per well were added on day 4. Cells were harvested at 
days 2 and 7 using Versene and were treated with citric acid/Tween 20 solution according to 
the method of Otto (212). A phosphate buffer containing DAPI for staining the cell 
suspension (0.25 x 10
6
 cells/ml) was used. Each histogram, depicting the DNA index and cell 
cycle distribution, represents 3 x 10
4 
- 9 x 10
4 
cells. The Multicycle program (Phoenix Flow 
Systems, CA, USA) was used for histogram analyses.  
 
Solutions Compounds     
Versene EDTA 
in PBS (pH 7.2) 
10 mM 
Citric Acid Solution Citric Acid 
Tween 20 
in ddH2O 
1 mM 
0.5% 
DAPI Staining Solution Na2HPO4 x 2H2O (pH 8) 
DAPI 
in H2O 
250 mM 
1 mM 
 
Table 4: Solutions for cell cycle analyses. 
 
3.3.3.3 Anchorage independent growth  
Soft agar assays were used to assess the effect of Hox-C9 on colony formation ability of 
neuroblastoma cells. Transgene-induced cells (1 x 10
4
 cells/well) were mixed with culture 
medium containing 0.8% ultra-low gelling temperature agarose (Sigma-Aldrich) with 
doxycycline (2 µg/ml) and plated on a pre-solidified layer of the same media containing 
1% agarose in 12-well plates. One additional ml of culture media containing doxycycline 
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(2 µg/ml) was added after solidification to the top layer, and cells were incubated for 2-3 
weeks at 37 °C. Media covering the agar was refreshed every 2-3 days with fresh 
doxycycline-containing media. Colonies were stained using 0.005% crystal violet 
(Invitrogen). Images were obtained with a JVC KY-F75U 3-colour CCD camera-equipped 
Leica DM IL LED microscope (Leica Biosystems, Wetzlar, Germany) using DISKUS 
Imaging software (Hilgers, Koenigswinter, Germany) and a standard digital camera. 
 
Soft Agar Media Compounds     
Base Agar Ultra-low gelling temp. agarose 
Tet-free FCS in RPMI-1640 
Doxycycline 
1%  
10%  
2 µg/ml  
Top Agar Ultra-low gelling temp. agarose 
Tet-free FCS in RPMI-1640 
Doxycycline 
0.8%  
10%  
2 µg/ml 
Media covering Agar Tet-free FCS in RPMI-1640 
Doxycycline 
10%  
 2 µg/ml  
Table 5: Solutions for anchorge-independent growth analyses. Abbreviation: temp., temperature. 
 
3.3.4 Cell viability analyses 
3.3.4.1 TUNEL assay 
The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP Nick End Labeling 
(TUNEL) analysis was performed using the In Situ Cell Death Detection Kit according to the 
manufacturer’s protocol (Roche, Mannheim, Germany). Cells were plated, induced for 
transgene expression (2 µg/ml) and were harvested at days 2 and 7 using Trypsin-EDTA. 
Cells were spotted on cytospin slides (3 x 10
4
 cells/slide), fixed with 4% paraformaldehyde 
for 1 h at room temperature, washed with PBS (pH 7.2) and permeabilized on ice for 2 min 
using Triton X-100/sodium citrate. After washing with PBS, fragmented DNA was detected 
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in apoptotic cells by adding TMR red dUTP to nicked ends of DNA (In Situ Cell Death 
Detection Kit, Roche). Slides were incubated for 1 h at 37 °C in the dark and washed with 
PBS three times. The slides were sealed with fluorescent mounting medium (Dako, Hamburg, 
Germany). Red-fluorescent, TUNEL-positive cells were counted manually using a 
fluorescence microscope (Leica DMRA). Total cell numbers in each field were determined by 
DAPI staining.  
 
Solutions Compounds  
Washing Buffer PBS (pH 7.4)  
Fixation Solution Paraformaldehyde in PBS (pH 7.4) 4%  
Permeabilization Solution Triton X-100 
Sodium Citrate in ddH2O 
0.1%  
0.1%  
DAPI Staining Solution DAPI in PBS (pH 7.4) 1 mM  
Table 6: Solutions for TUNEL analyses. 
 
3.3.4.2 Annexin-V binding assay  
Surface exposure of phosphatidylserine by apoptotic cells was measured using APC-coupled 
Annexin-V and 7-AAD (BD Biosciences, Heidelberg, Germany). Cells were seeded in 10 cm 
cell culture dishes at a density of 1 x 10
6 
cells/dish in 8 ml RPMI-1640 (10% Tet-free FCS, 2 
µg/ml doxycycline) and were harvested at days 2 and 7 using Trypsin-EDTA. Cells were 
washed twice with cold PBS (4 °C), dissolved in Annexin-V binding buffer (BD) at a 
concentration of 1 x 10
5 
cells/ml and stained with APC-coupled Annexin-V and 7-AAD for 15 
min at RT according to the manufacturer’s protocol. Apoptotic cells were detected by FACS 
(FACS Canto, BD) using DIVA software (BD).  
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3.3.4.3 Hypoploidy assay 
The extent of DNA fragmentation was evaluated in a hypoploidy assay as described 
elsewhere (213). In brief, cells were seeded in 10 cm cell culture dishes at a density of 
1 x 10
6 
cells/dish in 8 ml RPMI-1640 (10% Tet-free FCS, 2 µg/ml doxycycline), harvested at 
days 2 and 7 using Trypsin-EDTA and dissolved in PBS at a density of 2.5 x 10
4
 cells/ml. 
Cells were stained by adding 500 µl Nicoletti-Buffer to 200 µl of this cell suspension. The 
propidium iodide (PI) fluorescence of individual nuclei was measured by FACS (FACS 
Canto, BD) using DIVA software (BD).  
 
Solution Compounds  
Nicoletti Staining Solution Sodium-Citrate  
Triton X-100 
PI 
0.1%  
0.1%  
50 µg/ml 
Table 7: Nicoletti staining solution for hypoploidy analyses. 
 
3.3.5 In vivo growth properties 
A total of 32 six-week-old female athymic nude-Foxn1
nu
 mice (Harlan Laboratories, An 
Venray, Netherlands) were used for the establishment of neuroblastoma xenograft tumors 
(Permission ID: 8.87-50.10.37.09.300; LANUV NRW, Germany). Neuroblastoma cells were 
induced for transgene expression by applying 2 µg/ml doxycycline to the culture media, 
harvested 48 h post induction at 90% confluence using Trypsin-EDTA, and suspended in 
matrigel (BD). Eight mice per group were inoculated subcutaneously in the flank with either 
2.5 x 10
7
 IMR- 32 cells or 1.7 x 10
7
 SK-N-AS cells in 200 µl matrigel. All mice were fed 
doxycycline-containing food (SSNIFF, Soest, Germany) throughout the experiment, starting 7 
days before inoculation. Tumor volume (V) was calculated by using the formula V = (length x 
width x depth) / 2. Mice were sacrificed when the tumor reached a volume of about 1 cm
3
 or 
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after 35 days post inoculation. Tumors were weighed and analyzed by western blotting for 
Hox-C9 expression and by pathological evaluation after staining with Meyer’s hematoxylin 
and eosin using the Leica ST4040 linear staining system (Leica Biosystems). In addition, the 
impact of Hox-C9 on already established neuroblastoma tumors was investigated using SK-N- 
AS cells. Either 1.7 x 10
7
 SK-N-AS HOXC9-Off or SK-N-AS GFP-Off cells were suspended 
in 200 µl matrigel respectively and inoculated subcutaneously in the flank of athymic Nude-
Foxn1
nu 
mice (6/group). HOXC9 or GFP gene expression was induced after the tumor had 
reached a mean tumor volume of 144 ± 41 mm
3 
(120
 
± 25 mm
3 
in SK-N-AS GFP tumors and 
174 ± 36 mm
3
 in SK-N-AS HOXC9 tumors) by switching from standard diet to doxycycline 
containing diet. Mice were sacrificed when the tumor reached a volume of 1 cm
3
 or after 35 
days post inoculation. Tumors were weighed and analyzed by western blotting for Hox-C9 
expression and by pathological evaluation after staining with Meyer’s hematoxylin and eosin 
using the Leica ST4040 linear staining system (Leica Biosystems).  
 
3.4 Molecular Biology 
3.4.1 RNA isolation  
Total RNA was isolated using the TRIZOL reagent following the instructions of the supplier 
(Invitrogen). Either 30 mg tumor material or 1 x 10
6 
cells were suspended in 1 ml TRIZOL. 
After samples were homogenized in homogenization tubes prefilled with ceramic beads 
(Precellys Ceramic Kit 1.4 mm, Peqlab, Erlangen, Germany) using the FastPrep FP120 cell 
disrupter (Qbiogene Inc., Carlsbad, CA, USA), 200 µl chloroform were added and the 
suspension was thoroughly mixed. The reaction tubes were centrifuged (12000 g, 10 min, 
4 °C), the upper phase was removed, mixed with 500 μl isopropanol (100%) and 3 µl 
Glycogen, incubated for 10 min at RT and centrifuged again (12000 g, 10 min, 4 °C) to 
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precipitate the RNA. The pellet was washed with 500 μl ethanol (70%), centrifuged (7500 g, 
5 min, 4 °C) and dried at RT for 5 minutes. After dissolving the pellet in 10-50 µl of nuclease-
free water (USB, High Wycombe, UK), RNA concentrations were quantified by using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, North Carolina, USA). 
RNA integrity was assessed using the RNA 6000 Nano Kit (Agilent Technologies) according 
to the manufacturer’s protocol by using the 2100 Bioanalyzer (Agilent Technologies). 
 
3.4.2 DNA isolation 
Genomic DNA was isolated using the Gentra Puregene Tissue Kit following the instructions 
of the supplier (Qiagen, Hilden, Germany). DNA concentrations were quantified by using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies).  
 
3.4.3 cDNA synthesis  
First strand cDNA was synthesized in a total volume of 21 μl using 2 μg of total RNA, 500 ng 
of oligo-(dT12–18)-primers (Invitrogen) and SuperScript II reverse transcriptase according to 
the manufacturer’s protocol (Invitrogen). In brief, 2 µg of total RNA were diluted in nuclease-
free water (USB) to a volume of 11 µl, oligo-(dT12–18)-primers (1 μl of 0.5 µg/ml) and 
dNTP’s (1 µl, 10 mM each) were added and the solution was incubated at 65 °C for 5 min and 
then quickly chilled on ice. Next, a reaction mix consisting of 4 μl 5 x First Strand Buffer 
(Invitrogen), 2 µl DTT (0.1 M, Invitrogen) and 1 µl RNasin (40 U/µl, Promega) was pooled 
with the RNA/primer mixture and incubated for 2 min at 42 °C. SuperScript II reverse 
transcriptase (1 µl, 200 U/µl, Invitrogen) was added to the reaction mix. The Reverse 
Transcriptase was allowed to synthesize the cDNA in an incubation step at 42 °C for 2 h 
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followed by a denaturation step at 70 °C for 15 min. Un-transcribed RNA was digested by 
adding 1 µl E. coli RNase H (Invitrogen, 2 units) and incubation at 37 °C for 20 min.  
 
Reaction Mix  Temperature Time 
RNA (2 µg) 
Oligo-dT Primers (0.5 µg/ml) 
dNTP’s (10 mM each) 
 11 µl 
   1 µl 
   1 µl 
65 °C 
 Ice 
 
  5 min 
  1 min 
 
First Strand Buffer (5 x) 
DTT (0.1 M)  
RNAsin (40 U /µl) 
   4 µl 
   2 µl 
   1 µl 
42 °C   2 min 
SuperScript II reverse transcriptase  
(200 U/µl) 
   1 µl 42 °C  
70 °C 
  2 h 
15 min 
RNase H (2 U/µl)    1 µl 37 °C   2 min 
Table 8: cDNA synthesis. 
 
3.4.4 Whole Genome Amplification   
WGA (whole genome amplified) DNA of purified genomic DNA from primary 
neuroblastoma specimens and neuroblastoma cell lines was generated using the REPLI-g Kit 
according to the manufacturer’s protocol (Qiagen). DNA concentrations were quantified by 
using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies).  
 
3.4.5 Quantitative real-time reverse transcriptase-polymerase 
chain reaction  
For quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) 
analysis cells were harvested, washed once with PBS, and subsequently used for RNA 
isolation and cDNA synthesis. Quantitative RT-PCR was performed using the SYBR Green I 
reagent on the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster 
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City, CA). Quantitative RT-PCR reactions were performed in a total volume of 30 μl 
containing 26.8 μl of 1 x SYBR Green PCR master mix (Applied Biosystems), 0.4 μl 
undiluted first strand cDNA, and 1.4 μl of 2.5 µM forward and reverse primer (Invitrogen) 
each. To enable calculation of relative expression levels, serial cDNA dilutions (undiluted, 
1:5, 1:25, and 1:125) were used for the generation of standard curves of each gene separately. 
Oligonucleotides hybridizing specifically to corresponding sequences of control genes HPRT1 
and SDHA as well as target genes served as primers in PCR reactions (Table 10). 
Oligonucleotides were selected in successive exons (intron-spanning) for each gene to avoid 
amplification of contaminating genomic DNA. Quantitative RT-PCR reactions were 
performed in duplicates using 96-well optical reaction plates with optical caps (Applied 
Biosystems). Cycling conditions consisted of a single incubation step at 95 °C for 10 minutes, 
followed by 45 cycles of 15 seconds at 95 °C, 30 seconds at 60 °C and 30 seconds at 72 °C. 
To evaluate amplification of nonspecific products, aliquots of each reaction mixture were 
analyzed by agarose gel electrophoresis. 
 
qRT-PCR 
Reaction Mix  Thermal Profile Temp Time Cycle 
Number 
Forward Primer (2.5 µM) 
Reverse Primer (2.5 µM) 
Template cDNA  
1 x SYBR Green PCR 
Master Mix  
  1.4 µl 
  1.4 µl 
  0.4 µl 
26.8 µl 
 
Initial Denaturation 
 
Denaturation 
Annealing 
Elongation 
95 °C 
 
95 °C 
60 °C 
72 °C 
10 min 
 
15 sec 
30 sec 
30 sec 
1 x 
 
 
45 x 
Table 9: qRT-PCR reaction. Abbreviation: Temp, temperature.  
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qRT-PCR Primer 
 
Gene 
Symbol  
UCSC Annotation  Primer Sequence Dir 
BAX 
chr19:49458117-  
49464519 
5’-CATGTTTTCTGACGGCAACTTC-3’ for 
5’-AGGGCCTTGAGCACCAGTTT-3’ rev 
BCL-2 
chr18:60790579- 
60986613, complement 
5’-TCGCCCTGTGGATGACTGA-3’ for 
5’-CAGAGACAGCCAGGAGAAATCA-3’ rev 
REST 
chr04:57775079- 
57802010 
5’-AGCTACATGTGAACCCACGGCA-3’ for 
5’-TCAGGCAAGTCAGCCTCTCGT-3’ rev 
PTN 
chr07:136912092- 
137028546, complement 
5’-ACAATGCCGAATGCCAGAAG-3’ for 
5’-ACAGGTGACATCTTTTAATC-3’ rev 
NNAT 
chr20:36149607- 
 36152090 
5’-TCGGCTGAACTGCTCATC-3’ for 
5’-CGAAAAGCGAATCCTAC-3’ rev 
NTRK1 
chr01:1567830671- 
156851642 
5’-GAGTGGTCTCCGTTTCG-3’  for 
5’-GTAAGGAGAGGCCCTG-3’ rev 
NGFR 
chr17:47572655- 
47592382 
5’-ACAACCTCATCCCTGTCTATTGCT-3’ for 
5’-TGTTCCACCTCTTGAAGGCTATG-3’ rev 
OPHN1 
chrX:67262186- 
67653299, complement 
5’-GCGATAGTTAGCTCTCCCTG-3’ for 
5’-CATAACACTTGAGCCTCT-3’ rev 
DNER 
chr02:230222345- 
230579286, complement 
5’-AGTCTCAGTGGATTCACCTG-3’  for 
5’-CGTTGTTCTGGCACGGAG-3’ rev 
CD44 
chr11:35160417- 
35253949 
5’-CACCATGGACAAGTTTTGG-3’ for 
5’-CACGTGGAATACACCTGCAA-3’ rev 
SNPH 
chr20:1246960- 
 1289971 
5’-AGCAGCAATTCTGGCTCCTA-3’ for 
5’-GTCCTGTGTGTCCTTCAGC-3’ rev 
NEFM 
chr08:24771274- 
24776606 
5’-TATAGAAATCGCTGCGTACAG-3’ for 
5’-GGGTCGGTGTGTATACAGTG-3’ rev 
NEFL 
chr08:24808469- 
24814131, complement 
5’-CTCTGAAGGAGAAGCCGAGG-3’ for 
5’-TTCAGACTCTTCCTTGGCAG-3’ rev 
MAP2 
chr02:210444403- 
210598834 
5’-GCTCATCATGTACCTGGAGG-3’ for 
5’-ATGCCACGCTGGATCTGCCT-3’ rev 
NTS 
chr12:86268073- 
86276770 
5’-CATGAAGAGGAGCTTGTTGC-3’ for 
5’-TATTCTCATACAGCTGCCGTT-3’ rev 
SDHA 
chr05:218356- 
256815 
5’-TGGGAACAAGAGGGCATCTG-3’ for 
5’-CCACCACTGCATCAAATTCATG-3’ rev 
HPRT1 
chrX:133594175- 
133634698 
5’-TGACACTGGCAAAACAATGCA-3’ for 
5’-GGTCCTTTTCACCAGCAAGCT-3’ rev 
Table 10: qRT-PCR primers. Chromosomal positions are given according to hg 19 assembly at the 
UCSC Genome Browser. Abbreviations: for, forward; rev, reverse; Dir, Direction. 
 
3.4.6 Methylation analysis 
HOXC9 promoter methylation analyses were performed by Sequenom Inc. (Hamburg, 
Germany) as described elsewhere (214). Genomic DNA was isolated from primary 
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neuroblastoma specimens and neuroblastoma cell lines (Puregene Blood Core Kit B; Qiagen) 
and modified by sodium bisulphite using the EZ-96 DNA methylation kit according to the 
manufacturer’s protocol (Zymo Research, Orange, CA, USA). Selected DNA regions located 
in the HOXC9 promoter region were amplified by PCR using reverse primers that incorporate 
the T7 promoter sequence for in vitro transcription. PCR primers were designed by using 
Methprimer (www.urogene.org/methprimer/). Sequenoms MassARRAY platform based on 
MALDI-TOF mass spectrometry in combination with RNA base-specific cleavage 
(MassCLEAVE) were used for quantitative methylation analysis. Mass spectra were obtained 
by using a MassARRAY Compact MALDI-TOF (Sequenom). Epityper software 1.0 
(Sequenom) was used to generate spectra’s methylation ratios.  
 
Methylation Analysis Primer 
Ampl  
 
Amplicon 
Size (bp) 
CpG 
Sites 
Primer Sequence Dir 
1 281 9 
5’-ATGGGTATAGGGGTTTTTTAGATGA-3’ for 
5’-TCTACTCACAAAACAATCAAATCAA-3’ rev 
2 339 17 
5’-TTTTAGTTTATTTGAGAAGTTTTTGTGTT-3’ for 
5’-CCCTACTACTCCTAAAAAAAATACATACA-
3’ 
rev 
Table 11: Primers for methylation analysis. Abbreviations: Ampl, amplicon; Dir, direction; for, 
forward; rev, reverse. 
 
3.4.7 Sequencing 
3.4.7.1 Sequencing of the HOXC9 locus in neuroblastoma tumors and cell 
lines 
Sequencing was performed by Beckman Coulter Genomics (Danvers, MA, USA). WGA 
DNA of purified genomic DNA from primary neuroblastoma specimens and neuroblastoma 
cell lines was generated using the REPLI-g Kit according to the manufacturer’s protocol 
(Qiagen). Amplicons covering the first 500 nucleotides upstream of the HOXC9 
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transcriptional start site, 5’ UTR, 3’ UTR, exon 1 and exon 2 with exon/intron boundaries 
were designed using Beckman Coulter Genomics Linux-based amplicon design software. 
M13 tail sequences were added to the PCR primers. Sanger sequencing of the genomic region 
of HOXC9 were performed using BigDye Terminator v3.1 chemistry (Applied Biosystems) 
and sequences were delineated using an ABI PRISM 3730xl DNA Analyzer (Applied 
Biosystems).  
 
Amplification Primers 
Ampl Ampl 
(bp) 
Primer Sequence Dir 
1 580 
5’-GTAAAACGACGGCCAGTGGCCAGTGGCAGAAGAACG-3’ for 
5’-CAGGAAACAGCTATGACCAATACGGCGCGGATCAATGC-3’ rev 
2 549 
5’-GTAAAACGACGGCCAGTCTGCTTATGGGTGGACATGG-3’ for 
5’-CAGGAAACAGCTATGACCACGACGTGCTGAACACTGC-3’ rev 
3 535 
5’-GTAAAACGACGGCCAGTGGACTCGCTCATCTCTCACG-3’ for 
5’-CAGGAAACAGCTATGACCCCGGTTGTAAAGGAAAATTG-3’ rev 
4 590 
5’-GTAAAACGACGGCCAGTCGTCACTACGCCCTCAAGC-3’ for 
5’-CAGGAAACAGCTATGACCAGTGTCCTCCTCACCTCTTC-3’ rev 
5 599 
5’-GTAAAACGACGGCCAGTGGAGACAGGTTGGGAGAGG-3’ for 
5’-CAGGAAACAGCTATGACCCCTGTGCAATCCTCAGAAGG-3’ rev 
6 598 
5’-GTAAAACGACGGCCAGTGATTGAGAATGGGGATCAGG-3’ for 
5’-CAGGAAACAGCTATGACCGAATCCCTAAACCCCTCACC-3’ rev 
7 552 
5’-GTAAAACGACGGCCAGTCACTGGAGGCCAAACAGG-3’ for 
5’-CAGGAAACAGCTATGACCCCCAAATGCAATAACTGAAC-3’ rev 
8 537 
5’-GTAAAACGACGGCCAGTAGGGGCTTTGATAGCTTTGG-3’ for 
5’-CAGGAAACAGCTATGACCTGTGGGGTTTTTGTTTTTCC-3’ rev 
9 600 
5’-GTAAAACGACGGCCAGTCCGGGTTCTCAATCTCACC-3’ for 
5’-CAGGAAACAGCTATGACCCAGCCCTCACCCCTCAGC-3’ rev 
10 543 
5’-GTAAAACGACGGCCAGTGAGAAACTGCGTTCTCTTTCC-3’ for 
5’-CAGGAAACAGCTATGACCAGAAGGAGCCCATTCTCTGG-3’ rev 
 
Table 12: Primers for Amplification. Abbreviations: Ampl, amplicon; for, forward; rev, reverse; Dir, 
direction.  
 
3.4.7.2 Sequencing of Plasmid DNA  
Sequencing reactions were performed using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems) according to the method of Sanger (215). Sequences were 
delineated at the Cologne Centre of Genomics (Cologne, Germany) using an ABI PRISM 
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3730 DNA Analyzer (Applied Biosystems). Sequencing data were evaluated using Chromas 
Lite 2.01 software (Technelysium Pty Ltd, Queensland, Australia).  
 
Sanger Sequencing      
Reaction Mix  Thermal Profile Temp Time Cycle No 
Primer (2.5 µM) 
Template DNA (60-80 ng) 
5 x Sequencing Buffer  
Big Dye Reaction Mix  
ddH2O 
0.5 µl 
1.0 µl 
2.0 µl 
2.5 µl 
4.0 µl 
Initial Denaturation 
 
Denaturation 
Annealing 
Elongation 
95 °C 
 
96 °C 
55 °C 
60 °C 
  5 min 
 
10 sec 
  5 sec 
  4 min 
  1 x 
 
 
35 x 
 
Table 13: Sanger sequencing reaction. Abbreviations: Temp, temperature; No, number. 
 
3.4.8 Retroviral plasmids and cloning procedure 
The human HOXC9 coding sequence was obtained by PCR from the retroviral vector pBIG2r-
HOXC9, a kind gift of PD Dr. Malte Buchholz (Division of Gastroenterology, University 
Hospital, Philipps-Universitaet Marburg, Marburg, Germany). The PCR primer sequences 
were as follows: 5’-CTC AAG CTT TTA GGA CTG CTC CTT GTC-3’ (forward) and 5’-
CAG GAT CCA CCA TGT CGG CGA CGG GGC CCA TC-3’ (reverse), which contained 
restriction sites for HindIII and BamHI respectively. The resulting PCR products were 
purified using the QIAquick gel extraction kit (Qiagen) according to the manufacturer’s 
instructions. The HOXC9 coding sequence was cloned into the pRevTRE vector (Clontech) 
using the restriction enzymes HindIII/BamHI (NEB, Frankfurt am Main, Germany). The 
resulting plasmid was purified (NucleoBond Kit PC 500; Macherey-Nagel, Dueren, 
Germany), and the nucleotide sequence was confirmed by direct sequencing using the BigDye 
Terminator v3.1 sequencing kit (Applied Biosystems). The control plasmid pRevTRE-eGFP-
PRE was generated in parallel using the retroviral vector plasmid MP71-eGFP-PRE (216) as 
template. The enhanced GFP-PRE element was cloned by blunt end cloning into the 
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pRevTRE vector using the restriction enzymes NotI and HindIII. Blunt end polishing was 
carried out using Vent DNA Polymerase (NEB). 
 
Vector Description Ref. 
pRevTet-On MoMuLV based retroviral vector expressing rtTA  
(Clontech) 
(217) 
pRevTRE MoMuLV based retroviral vector (Clontech) (217) 
pBIG2r-HOXC9 bidirectional doxycycline-regulated retroviral vector 
expressing HOXC9 
(218) 
pMP71-eGFP-PRE retroviral vector containing a enhancer element for GFP 
expression 
(216) 
pHIT G VSV-G expression vector (219, 220) 
Table 14: Retroviral plasmids. 
 
3.4.9 Immunobloting 
Immunoblots were prepared using the NuPAGE electrophoresis system (Novex Mini Cell; 
Invitrogen) and semi-dry blotting (Biometra, Goettingen, Germany) (221). For each sample, 
either 10-50 μg of total protein or cytosolic cell extracts were separated by SDS-PAGE in 4%-
12% Bis-Tris gels (Invitrogen) and transferred to 0.2 µm nitrocellulose membranes 
(Invitrogen) by semi-dry blotting. The membranes were blocked with 5% skim milk powder 
(Heirler Canovis, Radolfzell, Germany) in 0.05% Tween 20/PBS before incubation with 
primary antibody and horseradish peroxidase-labeled secondary antibody. The antigen-
antibody complex was detected either with Visualizer Spray & Glow (Upstate, 
Schwalbach, Germany) or with Supersignal West Femto (Thermo Fisher Scientific, 
Braunschweig, Germany). For isolation of cytosolic cell extracts, 1 x 10
7 
cells were washed 
twice with PBS at 4 °C. Cells were resuspended in 50 µl of buffer A and incubated for 20 min 
on ice for swelling. After addition of mannitol and sucrose to a final concentration of 220 mM 
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and to 68 mM (buffer B), respectively, cells were cracked by passing through a 27-gauge 
needle. Cell breakage was verified microscopically using trypan blue exclusion. Membranes 
were pelleted at 14000 g and 4 °C for 20 min, and the resulting supernatants were recovered 
(cytosolic extract). Total protein extracts were isolated either with Cell Lysis Buffer 
(Biovision, Hannover, Germany) or RIPA Buffer supplemented with PMSF and Complete 
Protease Inhibitor Cocktail (Roche). 
 
Cell Lysis    
Buffer Compounds  
RIPA Buffer Nonidet P 40 
Sodium Deoxycholate 
SDS 
in PBS (pH 7.2) 
1.0% 
0.5% 
0.1% 
Cell Lysis Buffer PMSF 
Complete Protease Inhibitor 
Cocktail  
in RIPA Buffer 
0.02 mM 
1      mM 
 Buffer A 
(Cytosol Extraction Buffer) 
PIPES (pH 7.0) 
KCl 
MgCL2 
EGTA 
Cytochalasin B 
Complete Protease Inhibitor 
Cocktail  
DTT 
50 mM 
50 mM 
  2 mM 
  5 mM 
  1 µM 
  1 mM 
    
  1 mM 
Buffer B 
(Cytosol Extraction Buffer)  
Mannitol 
Sucrose 
220 mM 
  68 mM 
Table 15: Cell lysis buffer.  
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Immunoblotting   
Solutions Compounds  
MOPS SDS Running Buffer 
(Invitrogen) 
MOPS 
Tris-Base (pH 7.7) 
EDTA 
SDS 
50 mM 
50 mM 
  1 mM 
  0.1% 
Tris-Glycine Transfer Buffer Tris-Base (pH 8.3) 
Glycine  
Methanol 
  25 mM 
150 mM 
  10%  
Blocking/Hybridization 
Solution 
Skim Milk Powder 
Tween 20 
in PBS (pH 7.2) 
5%  
0.05% 
Table 16: Solutions for immunoblotting. 
 
Hybridization     
Antibodies Company Product No Dilution 
anti-HOXC9 Abcam ab50839 1 :     100 
anti-BCL-2 Dako M0887 1 :     500 
Anti-MYCN Santa Cruz sc53993 1 :   1000 
anti-cleaved Caspase 3 (Asp 175) NEB 9664 1 :   1000 
anti-cleaved Caspase 7 (Asp 198) NEB 9491 1 :   1000 
anti-cleaved Caspase 9 (Asp 330) NEB 9501 1 :   1000 
anti-cleaved Caspase 9 (Asp 315) NEB 9505 1 :   1000 
polyclonal goat anti-mouse (HRP) Dako P0447 1 :   1000 
polyclonal goat anti-rabbit (HRP) NEB 7074S 1 :   1000 
polyclonal goat anti-rabbit (HRP) Dako P0448 1 :   1000 
anti-beta-Actin Abcam ab8227 1 : 10000 
 
Table 17: Antibodies for immunoblotting. Abbreviation: No, number. 
 
3.4.10 Immunofluorescence 
3.4.10.1 Hox-C9 immunofluorescence  
The localization of transgenic Hox-C9 was determined by immunofluorescence. Cells were 
seeded on Chamber Slides (Nunc, Wiesbaden, Germany), induced for transgene expression 
(2 µg/ml) and grown for 48 h. Cells were fixed using 4% paraformaldehyde, and 
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permeabilized for 5 min using Triton X-100 in PBS. After washing thrice using PBS, cells 
were blocked with 1% BSA in PBS for 30 minutes. Cells were incubated for 1 h with anti-
Hox-C9 antibody (1:5 dilution, Abcam) at RT, washed thrice with PBS and incubated for 
30 min with TRITC-labeled polyclonal rabbit anti-mouse antibody (1:20 dilution, Dako) 
at RT. Images were obtained with a JVC KY-F75U 3-colour CCD camera linked to a 
Leica DMRA microscope (Leica) using DISKUS Imaging software (Hilgers). 
 
Immunofluorescence   
Solutions Compounds  
Fixation  
Permeabilization  
Blocking/Hybridization  
Paraformaldehyde in PBS (pH 7.4) 
Triton X-100 in PBS (pH 7.4) 
BSA in PBS (pH 7.4) 
4% 
0.2% 
1% 
Table 18: Solutions for immunofluorescence (Hox-C9 staining).  
 
Antibodies Company Product No Dilution 
anti-HOXC9 
rabbit anti-mouse IgG (TRITC) 
Abcam 
Dako 
ab50839 
R 0270 
1 :   5 
1 : 20 
 
Table 19: Antibodies for immunofluorescence. Abbreviation: No, number. 
 
3.4.10.2 F-Actin cytoskeleton staining  
The F-Actin cytoskeleton of differentiating IMR-32 cells was stained using Rhodamine 
Phalloidin (Cytoskeleton Inc., Denver, CO, USA). Cells were seeded on Chamber Slides 
(Nunc), induced for transgene expression (2 µg/ml) and grown for 18-21 days. Cells were 
fixed using 4% paraformaldehyde and permeabilized for 5 min using 0.5% Triton X-100 in 
PBS. After washing thrice with PBS, cells were incubated with 0.1 mM Rhodamine 
Phalloidin for 30 min at RT. After washing thrice with PBS, cells were counterstained with 
DAPI. Images were obtained with a JVC KY-F75U 3-colour CCD camera linked to a 
Leica DMRA microscope (Leica) using DISKUS Imaging software (Hilgers). 
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F-Actin staining   
Solutions Compounds  
Fixation  
Permeabilization  
Rhodamine Phalloidin 
DAPI Staining Solution 
Paraformaldehyde in PBS (pH 7.4) 
Triton X-100 in PBS (pH 7.4) 
Rhodamine Phalloidin in PBS (pH 7.4) 
in PBS (pH 7.4) 
4% 
0.5% 
1 mM 
1 mM 
Table 20: Solutions for immunofluorescence (F-Actin staining). 
 
 
 Results 
 
 47 
4. Results 
4. 1 HOX gene expression in neuroblastoma  
The expression patterns of 39 class I HOX genes were examined in 649 neuroblastoma 
samples by microarray analysis, and the association with prognostic markers and patient 
outcome was determined. The expression of the majority of HOX genes correlated 
significantly with clinical covariates in neuroblastoma (Table 21). Elevated expression of 
HOXD genes, particularly HOXD3, HOXD8, HOXD9 and HOXD10, was predominantly 
associated with unfavorable prognostic markers and poor patient outcome (Table 21, Figures 
5 and 6). Similarly, I observed increased expression levels of more posterior HOX genes 
(HOXA10, HOXA11, HOXA13, HOXC12, HOXC13) in neuroblastomas with unfavorable 
characteristics (Table 21). In contrast, elevated expression of the majority of the remaining 
HOX genes was significantly correlated with favorable prognostic markers and beneficial 
outcome (Table 21). HOX gene expression values and the association with prognostic markers 
and patient outcome are available through Kocak et al., Supplementary Table S1 (222). 
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Probe ID Gene Age Stage MYCN 1p PAM EFS OS 
A_24_P200854 HOXA2             
A_23_P253982 HOXA4             
A_24_P416370 HOXB4             
A_23_P363316 HOXB5             
A_23_P66682 HOXB6             
A_23_P27013 HOXB9             
A_24_P124558 HOXC8_2             
A_23_P398476 HOXC8             
A_23_P25150 HOXC9             
A_24_P218805 HOXC10             
A_23_P36546 HOXC10_2             
A_23_P501538 HOXA3_2             
A_23_P93772 HOXA5             
A_23_P70968 HOXA7             
A_23_P500998 HOXA9             
A_24_P399220 HOXB3_2             
A_23_P316511 HOXB3             
A_23_P55281 HOXB7             
A_23_P370588 HOXB8             
A_23_P389281 HOXA13_2             
A_24_P914411 HOXC6_2             
A_23_P150974 HOXC4             
A_23_P2344 HOXC6             
A_23_P107283 HOXB2_2             
A_23_P82370 HOXA6             
A_23_P111571 HOXA3             
A_24_P77904 HOXA10_2             
A_23_P47941 HOXC11             
A_23_P120243 HOXD1             
A_23_P165796 HOXD13             
A_23_P253368 HOXA10             
A_23_P64808 HOXC13             
A_23_P323180 HOXD3             
A_23_P210164 HOXD8             
A_23_P429383 HOXD9             
A_23_P381368 HOXD10             
A_23_P31306 HOXA13             
A_23_P162355 HOXC5             
A_23_P345725 HOXD4             
A_23_P154420 HOXD12             
A_24_P365015 HOXB13             
A_23_P143029 HOXD11             
A_23_P335981 HOXC12             
A_23_P42706 HOXA11             
A_23_P145752 HOXA1             
A_23_P118675 HOXB1             
A_24_P33077 HOXB2             
 
Table 21: HOX gene expression and association with prognostic markers and patient outcome in 
neuroblastoma. Age (< 18 months vs. > 18 months), stage (localized vs. 4 vs. 4S), MYCN amplification 
status (non amplified vs. amplified), 1p status (normal vs. aberrant), gene expression-based 
classification (favorable vs. unfavorable). Green, high expression is significantly associated with 
favorable prognostic markers/outcome (e.g. age < 18 months, p < 0.05); red, high expression is 
significantly associated with unfavorable prognostic markers/outcome (e.g. age > 18 months, 
p < 0.05); grey, no significant association with the corresponding prognostic marker/outcome. 
HOX_2, second HOX probe of the corresponding HOX gene on the Array.  
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Figure 5: Correlation of HOXD3, HOXD8, HOXD9 and HOXD10 expression levels with prognostic 
markers in neuroblastoma. Association of tumor stage, age at diagnosis, MYCN amplification status, 
chromosome 1p status and gene expression-based classification (PAM classifier) with HOX transcript 
levels in 649 neuroblastoma samples as determined by oligonucleotide-microarray experiments. 
Boxes, median expression values (horizontal line) and 25th and 75th percentiles; whiskers, distances 
from the end of the box to the largest and smallest observed values that are less than 1.5 box lengths 
from either end of the box; open circles, outlying values; asterisks, extreme outlying values. 
Abbreviations: amp., amplification; norm., normal, aberr., aberration; fav., favorable; unfav., 
unfavorable. 
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Figure 6: Survival of neuroblastoma patients according to expression levels of HOXD3, HOXD8, 
HOXD9 and HOXD10. Kaplan-Meier curves show the probability of EFS and OS according to 
HOXD3, HOXD8, HOXD9 and HOXD10 expression as determined by microarray analysis. “HOX 
high”, “HOX intermediate-high”, “HOX intermediate-low” or “HOX low” indicate patients with HOX 
mRNA levels defined as high (> 75th percentile), intermediate-high (> 50th and < 75th percentile), 
intermediate-low (< 50 and > 25th percentile) or low (< 25th percentile), respectively.  
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4.1.1 Prediction of neuroblastoma outcome based on a HOX gene 
expression-based classifier 
To assess the impact of class I HOX gene expression on neuroblastoma outcome, we 
developed a HOX gene expression-based classifier (Table 22) using a training cohort of 75 
neuroblastoma patients with maximal divergent clinical outcome (as described in Materials 
and Methods). In the training set, the classification accuracy was 85% as assessed by cross-
validation (Table 23). In an independent validation subset of 215 patients who matched the 
outcome criteria of the training set, the 33 HOX gene signature predicted patient outcome with 
an accuracy of 76% (Table 24). In the entire validation set (n= 574), the classifier accurately 
discriminated patients with favorable and unfavorable outcome (favorable, n= 265; 5-year 
EFS 80.7 ± 2.6%, 5-year OS 96.0 ± 1.2%; unfavorable, n= 309; 5-year EFS 49.5 ± 3.0%, 5-
year OS 67.1 ± 2.8%; both p < 0.001; Figure 7a and b). In multivariate Cox regression models 
based on EFS and OS, the HOX classifier predicted patient outcome independently from age, 
stage and MYCN amplification status (Table 25).  
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Probe ID Gene Symbol Selection frequency of HOX probes 
(5CVx10repeats) 
A_23_P25150 HOXC9 50 
A_24_P218805 HOXC10 50 
A_23_P398476 HOXC8 50 
A_23_P36546 HOXC10_2 50 
A_23_P345725 HOXD4 50 
A_23_P150974 HOXC4 50 
A_24_P124558 HOXC8_2 50 
A_23_P27013 HOXB9 50 
A_23_P55281 HOXB7 50 
A_23_P389281 HOXA13_2 50 
A_23_P429383 HOXD9 49 
A_23_P323180 HOXD3 49 
A_23_P47941 HOXC11 49 
A_24_P77904 HOXA10_2 48 
A_23_P107283 HOXB2_2 48 
A_23_P500998 HOXA9 48 
A_23_P70968 HOXA7 48 
A_23_P335981 HOXC12 47 
A_23_P381368 HOXD10 47 
A_23_P363316 HOXB5 46 
A_23_P66682 HOXB6 45 
A_23_P210164 HOXD8 45 
A_23_P253368 HOXA10 44 
A_23_P501538 HOXA3_2 44 
A_23_P370588 HOXB8 44 
A_24_P416370 HOXB4 44 
A_23_P64808 HOXC13 43 
A_23_P2344 HOXC6 42 
A_24_P200854 HOXA2 42 
A_23_P253982 HOXA4 42 
A_23_P154420 HOXD12 41 
A_24_P365015 HOXB13 40 
A_24_P33077 HOXB2 40 
A_24_P399220 HOXB3_2 38 
A_24_P914411 HOXC6_2 38 
A_23_P82370 HOXA6 37 
A_23_P93772 HOXA5 36 
A_23_P162355 HOXC5 36 
A_23_P316511 HOXB3 34 
A_23_P31306 HOXA13 32 
 
Table 22: HOX classifier probes. Selection frequency of HOX probes in 50 models generated in the 
iterative cross-validation process. Probes were selected for the final classifier when they were included 
in at least 65% of the models. HOX_2, second HOX probe of the corresponding HOX gene on the 
array. Abbreviation: CV, cross validation. 
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Figure 7: Survival curves of neuroblastoma patients according to classification results of the HOX 
classifier. Kaplan-Meier estimates for (a) OS and (b) EFS of the entire validation set (n= 574) 
according to classification results of the HOX classifier. Abbreviations: unfav., unfavorable; fav., 
favorable.  
 
 
Classification performance of the HOX classifier in the training set 
   (%) 
Classifier Patients (N) Probes (N) Accuracy Sensitivity  Specificity 
NB_d75_hox52_fsPAM_predSVM 75 52 85 58 96 
Table 23: Classification performance of the HOX classifier in the training set.  
 
 
Classification performance of the HOX classifier in the selected test set  
   (%) 
Classifier Patients (N) Probes (N) Accuracy Sensitivity  Specificity 
NB_d75_hox52_fsPAM_predSVM 215 40 76 63 90 
Table 24: Classification performance of the HOX classifier in the test set matching the criteria of the 
training set. 
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Multivariate Cox regression models for the entire test set based on EFS and OS  
considering single prognostic markers and the HOX classifier 
Marker Patients 
(N) 
Available  
Cases (N) 
Hazard  
Ratio 
95% CI p 
Model considering single prognostic markers  
and the HOX classifier based on EFS   
574 547  
Age (< 18 months vs. > 18 months)   2.06 1.48 – 2.87 < 0.001 
Stage (1-3, 4S vs. 4)   1.49 1.49 – 2.07    0.018 
MYCN status (normal vs. amplified)   1.44 1.44 – 2.03    0.041 
HOX classifier (favorable vs. unfavorable)   2.13 1.48 – 3.06 < 0.001 
Model considering single prognostic markers 
and the HOX classifier based on OS 
574 568  
Age (< 18 months vs. > 18 months)   4.44 2.61 – 7.53 < 0.001 
Stage (1-3, 4S vs. 4)   2.24 1.39 – 3.58 < 0.001 
MYCN status (normal vs. amplified)   2.62 1.77 – 3.88 < 0.001 
HOX classifier (favorable vs. unfavorable)   3.10 1.67 – 5.76 < 0.001 
 
Table 25: Multivariate Cox regression models for the complete test set based on EFS and OS 
considering single prognostic markers and the HOX classifier. Abbreviation: CI, Confidence Interval. 
 
 
4.2 Elevated HOXC9 expression is associated with 
favorable prognostic markers, beneficial patient outcome 
and spontaneous regression in neuroblastoma 
HOXC9 was most strongly associated with the clinical neuroblastoma phenotype. Elevated 
HOXC9 expression levels strongly correlated with lower stages, age < 18 months at diagnosis, 
lack of MYCN amplification, lack of 1p loss, and favorable gene expression-based 
classification according to the PAM classifier (Figure 8a). Multivariate Cox regression 
models based on EFS and OS considering established risk markers (MYCN status, tumor stage 
and patient age at diagnosis) identified HOXC9 expression as a significant independent 
prognostic marker for both EFS and OS (Table 26). I also investigated HOXC9 expression 
levels in infant neuroblastoma that had regressed without any chemotherapy, and compared 
these to infant stage 4 neuroblastoma. Notably, HOXC9 transcript levels were significantly 
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higher in neuroblastoma showing spontaneous regression (Figure 8b). Furthermore, patients 
with high HOXC9 expression levels had a significantly better outcome with a 5-year OS of 95 
± 2% as compared to patients with low HOXC9 expression (5-year OS of 56 ± 5%; Figure 
8c). Likewise, HOXC9 expression levels strongly correlated with EFS (high HOXC9 
expression, 5-year EFS 82 ± 4% vs. low HOXC9 expression, 5-year EFS 37 ± 5%; Figure 8d). 
Taken together, these results demonstrate that HOXC9 transcript levels discriminate 
neuroblastoma patients with favorable and unfavorable outcome and indicate that elevated 
HOXC9 expression is associated with spontaneous regression in neuroblastoma. 
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Figure 8: Association of HOXC9 expression with prognostic markers and survival in neuroblastoma. 
(a) Association of HOXC9 expression with prognostic markers in 649 neuroblastomas as determined 
by microarray analysis. PAM classifier, gene expression-based classifier as defined in the main text. 
Boxes, median expression values (horizontal line) and 25th and 75th percentiles; whiskers, distances 
from the end of the box to the largest and smallest observed values that are less than 1.5 box lengths 
from either end of the box; open circles, outlying values; asterisks, extreme outlying values. (b) 
HOXC9 expression levels in spontaneously regressing and stage 4 infant neuroblastomas. (c) OS 
probability of neuroblastoma patients according to HOXC9 expression. (d) EFS probability of 
neuroblastoma patients according to HOXC9 expression. Abbreviations: amp., amplification; norm., 
normal; aberr., aberration; fav., favorable; unfav., unfavorable; SR, spontaneous regressive; NB, 
neuroblastoma.  
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Multivariate Cox regression models based on EFS and OS  
considering single prognostic markers and HOXC9 expression 
Marker 
Patients 
(N) 
Available  
Cases (N) 
Hazard  
Ratio 
95% CI  p 
Model considering single prognostic markers 
and HOXC9 expression based on EFS   
649 622  
Age (> 18 months vs. < 18 months)   0.48 0.34 – 0.66 < 0.001 
Stage (4 vs. 1-3, 4S)   0.52 0.38 – 0.72 < 0.001 
MYCN status (amplified vs. normal)   0.57 0.42 – 0.79    0.001 
HOXC9 expression (continuous)   0.75 0.60 – 0.93    0.012 
Model considering single prognostic markers 
and HOXC9 expression based on OS 
649 643  
Age (> 18 months vs. < 18 months)   0.24 0.15 – 0.39 < 0.001 
Stage (4 vs. 1-3, 4S)   0.33 0.26 – 0.52 < 0.001 
MYCN status (amplified vs. normal)   0.32 0.22 – 0.46 < 0.001 
HOXC9 expression (continuous)   0.73 0.55 – 0.97    0.030 
Table 26: Multivariate Cox regression models based on EFS and OS considering single prognostic 
markers and HOXC9 expression. Multivariate Cox regression models based on EFS and OS 
considering age at diagnosis (> 18 months vs. < 18 months), stage (4 vs. 1-3, 4S), MYCN status 
(amplified vs. normal) and HOXC9 expression (continuous). Abbreviation: CI, Confidence Interval. 
 
4.2.1 Elevated HOXC9 expression is associated with abdominal 
neuroblastoma  
Since the expression of class I HOX genes is not only temporally but also spatially regulated 
during embryonic development, HOXC9 expression in neuroblastoma was investigated 
according to the primary tumor site. I observed significantly higher HOXC9 expression levels 
in tumors with abdominal location in comparison to neuroblastomas located at the neck/chest 
or at the adrenal glands (Figure 9a), which is in line with the embryonal expression pattern of 
HOX genes: HOX genes located more 5’ in the HOX cluster, such as HOXC9, are expressed 
more posterior in the body during development (Figure 4). Analogous expression patterns 
were observed for HOXA9, HOXA10 and HOXC10 (Figure 10). The remaining 5’ located 
HOX genes showed no significant correlation with the primary tumor localization (Figure 10). 
Interestingly, the spatial expression pattern of HOXC9 does not correlate with the general 
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association of primary tumor sites with patient outcome. In line with previous reports (223-
225), I observed a better outcome of patients with neck/chest neuroblastoma in comparison to 
tumors located at the adrenal glands or in the abdomen (neck/chest vs. adrenal glands vs. 
abdomen, 5-year EFS, 84 ± 5% vs. 69 ± 3% vs. 63 ± 4%, respectively; 5-year OS, 97 ± 2% vs. 
83 ± 2% vs. 85 ± 3%, respectively; Figure 9b and 9c).  
 
 
Figure 9: Association of HOXC9 expression with tumor localization and survival of neuroblastoma 
patients according to the site of primary tumor. (a) Association of HOXC9 expression with tumor 
localization in 480 neuroblastomas as determined by microarray analysis. Boxes, median expression 
values (horizontal line) and 25th and 75th percentiles; whiskers, distances from the end of the box to 
the largest and smallest observed values that are less than 1.5 box lengths from either end of the box; 
open circles, outlying values; asterisks, extreme outlying values. Survival of neuroblastoma patients. 
(b) EFS and (c) OS probability of neuroblastoma patients according to the site of primary tumor. 
Abbreviations: NK/C, neck/chest; ABD, abdomen; AG, adrenal glands, loc., localization. 
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Figure 10: Expression of 5’ clustered HOX genes according to primary tumor localization. Boxes, 
median expression values (horizontal line) and 25th and 75th percentiles; whiskers, distances from the 
end of the box to the largest and smallest observed values that are less than 1.5 box lengths from either 
end of the box; open circles, outlying values; asterisks, extreme outlying values. Abbreviations: NK/C, 
neck/chest; ABD, abdomen; AG, adrenal glands, loc., localization. 
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4.3 Molecular basis for differential expression of HOXC9 
in neuroblastoma  
4.3.1 Numerical gain of chromosome 12 correlates with elevated 
expression of HOXC9  
I next aimed to evaluate whether genetic or epigenetic aberrations of the HOXC9 locus 
(12q13.3) are associated with HOXC9 expression levels. First, I analyzed aCGH profiles of 
209 neuroblastoma samples and compared the results with corresponding microarray gene 
expression data of the same tumors. Genomic aberrations of chromosome 12 were detected in 
92/209 of the samples (44%, Table 27, Figure 11a). I most frequently observed numerical 
gains of the entire chromosome (n= 64, 30.6%). Numerical chromosome 12 loss occurred in 4 
cases. Segmental alterations of chromosome 12 were detected in 24 tumors (11.5%), most of 
which were segmental gains not affecting the HOXC9 locus (n= 18, 8.6%). Analysis of 
HOXC9 gene expression data revealed significantly higher transcript levels in tumors with 
numerical chromosome 12 gains in comparison to tumors in which the HOXC9 locus was not 
affected by genomic alterations (Figure 11b). 
 
Aberration Patients (N) 
No Aberrations 117 
Whole Chromosome gain  64 
Whole Chromosome loss 4 
Segmental gain (HOXC9 affected) 2 
Segmental gain (HOXC9 not affected) 18 
Segmental loss (HOXC9 affected) 0 
Segmental loss (HOXC9 not affected) 4 
Total  209 
Table 27: Aberrations on chromosome 12 as determined by aCGH.  
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Figure 11: Aberrations at chromosome 12 and correlation with HOXC9 expression. (a) Chromosomal 
aberrations of the HOXC9 locus in primary neuroblastomas (n= 200). (b) Association of whole 
chromosome 12 gain with HOXC9 expression in primary neuroblastomas. Abbreviations: aberr., 
aberration; NG, numerical gain. 
 
 
4.3.2 Sequencing of HOXC9 
To examine whether inactivating mutations might contribute to diminished HOXC9 
expression in neuroblastoma, we sequenced the genomic HOXC9 locus of 46 primary tumors 
which showed low HOXC9 expression. A total of 16 unique sequence variants were detected 
(Table 28). Eight of these represented known SNP’s, while the remaining sequence variants 
were novel. The latter variants affected either non-coding sequences or were synonymous, 
and occurred infrequently in our cohort. Together, these data suggest that mutations in the 
HOXC9 locus are not a major cause of reduced HOXC9 expression levels in unfavorable 
neuroblastoma.  
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Chromosomal 
Position 
A 1 A 2 REG 
 
DB 
SNP 
AA 
(A 1) 
AA 
(A 2) 
AA  
CO 
AA 
CD 
Freq 
 
chr12:52,679,605 T A Intr    0  1 
chr12:52,679,904 T G Intr    0  1 
chr12:52,680,032 G C Intr    0  3 
chr12:52,680,037 A G Intr 56368105   0  29 
chr12:52,680,041 G A Intr 12817092   0  35 
chr12:52,680,050 G C Intr 56154542   0  27 
chr12:52,680,263 T C Cod  Ser Ser 8 AG_ 1 
chr12:52,680,551 C T Cod 34079606 Val Val 104 GT_ 1 
chr12:52,680,764 C T Cod 2241820 Ala Ala 175 GC_ 33 
chr12:52,680,844 C A Intr    0  2 
chr12:52,681,051 A G Intr 67918869   0  10 
chr12:52,682,790 A G UTR3    0  1 
chr12:52,683,065 A G UTR3    0  2 
chr12:52,683,165 C G UTR3 72033532   0  3 
chr12:52,683,238 A G UTR3 1867297   0  3 
chr12:52,683,242 C G UTR3    0  1 
Table 28: Sequence variations in the genomic region of HOXC9. Chromosomal positions are given 
according to hg 18 assembly at the UCSC Genome Browser. Abbreviations: A, Allele; REG, Region; 
Intr, intronic; Cod, coding; AA Amino Acid; CO, coordinate; CD, Codon; Freq; Frequency.  
 
4.3.3 Methylation pattern of the promoter region of HOXC9 
To determine whether epigenetic regulation might contribute to differences in HOXC9 
expression in neuroblastoma, we analyzed the methylation status of 26 CpG sites located in 
the HOXC9 promoter region. DNA samples from 46 neuroblastoma tumors with differing 
HOXC9 expression levels (high and low HOXC9 expression as defined in Materials and 
Methods, n= 23 per subgroup) and 2 neuroblastoma cell lines (SK-N-AS and IMR-32) with 
loss of HOXC9 expression were analyzed (Table 29). Unsupervised one-way hierarchical 
clustering of CpG site methylation revealed a largely homogeneous methylation pattern in 
tumors of both subgroups and cell lines (Figure 12), suggesting that down-regulation of 
HOXC9 does not result from differences in CpG methylation patterns.  
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Design statistics of genomic regions analyzed for methylation 
Number of DNA samples 48 
Number of genomic regions 1 
Number of amplicons 2 
Number of CpG units 26 
Median amplicon length 310 bp (min= 281; max= 339) 
Median CpG/amplicon 13 CpG/amplicon (min= 9; max= 17) 
 
Table 29: HOXC9 promoter methylation analyses. Design statistics of genomic regions analyzed for 
methylation. Abbreviations: min, minimum; max, maximum. 
 
 
 
 
 
 
Figure 12: Hierarchical clustering of methylation ratios. A total of 26 CpG units of HOXC9 were 
analyzed in 46 tumor samples and 2 cell lines (red, upper: SK-N-AS; lower: IMR-32). HOXC9 
expression (blue, low; green, high) and risk group according to INRG (blue, HR; green, LR/IR and 
grey, unclassified) are indicated aside. DNA methylation values are indicated by colors ranging from 
dark red (non-methylated) to bright yellow (30% methylated). Poor quality data are indicated in grey. 
A histogram is given in the inset that indicates the frequency of each color in the hierarchical 
clustering. Abbreviations: HR, high-risk; LR, low-risk; IR, intermediate-risk; INRG, International 
Neuroblastoma Risk Group. 
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4.4 Functional investigation of HOXC9 in neuroblastoma 
4.4.1 Doxycycline-inducible expression of HOXC9 in 
neuroblastoma cell lines 
The expression of HOXC9 was restored in three neuroblastoma cell lines to analyze its 
functional effects on growth characteristics of neuroblastoma. To mirror the broad spectrum 
of neuroblastoma disease, I selected two MYCN-amplified (IMR-32 and CHP-212) cell lines 
and one non-amplified (SK-N-AS) cell line. Either HOXC9 or GFP control cDNA was placed 
under a tetracycline-regulated promoter. Transgenic polyclonal cell lines were further verified 
for Hox-C9 expression by Western blot analysis (Figure 13a and b) and 
immunohistochemistry (Figure 14). Recombinant Hox-C9 expression, which was already 
detected under uninduced conditions due to promoter leakage of the pRevTRE vector system, 
increased in a time dependent manner upon treatment with doxycycline (Figure 13b) and 
reached protein levels in the range of physiological levels observed in neuroblastoma patients 
with high expression of Hox-C9 (Figure 13c). The expression of recombinant Hox-C9 was 
observed in the nucleus (Figure 14).   
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Figure 13: Inducible expression of Hox-C9 in SK-N-AS, IMR-32 and CHP-212 cells and 
physiological Hox-C9 levels in primary neuroblastomas as determined by Western blot analysis. (a) 
Inducible expression of Hox-C9 vs. GFP-expressing control cells. (b) Time course of Hox-C9 
expression. (c) Representative neuroblastoma tumor samples with high and low Hox-C9 expression 
(high and low HOXC9 expression as defined in Materials and Methods).  
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Figure 14: Inducible expression of Hox-C9 in SK-N-AS and IMR-32 cells as determined by 
immunohistochemistry. Hox-C9 On vs. Hox-C9 Off vs. parental neuroblastoma cell lines. 
 
 
4.4.2 HOXC9 expression inhibits neuroblastoma cell growth  
4.4.2.1 HOXC9 expression inhibits growth of neuroblastoma cells in vitro  
To investigate whether HOXC9 expression affects growth properties of neuroblastoma cell 
lines, polyclonal HOXC9-expressing SK-N-AS, IMR-32 and CHP-212 cells were compared 
with polyclonal GFP-expressing controls. Cell proliferation was assayed for up to 8 days 
using trypan blue dye exclusion tests. In all cell lines, the number of viable cells at day 8 was 
significantly lower compared to GFP-induced controls (Figure 15a).  
To determine whether reduced proliferation upon HOXC9 re-expression might be due 
to impaired cell cycle progression, the DNA content of HOXC9-expressing cells was assessed 
by flow cytometry. I observed a significant increase of the G0/G1 peak at day 7 after Hox-C9 
induction in all three cell lines (Figure 15b).  
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To investigate the influence of HOXC9 on anchorage-independent clonal growth, I 
preformed soft agar assays with SK-N-AS and IMR-32 cells which show anchorage 
independent growth potential. A marked reduction in colony formation was observed in both 
HOXC9-expressing SK-N-AS and IMR-32 cell lines in comparison to GFP-expressing 
control cells (Figure 15c).  
 
 
 
Figure 15: HOXC9 re-expression inhibits growth of neuroblastoma cells in vitro. Hox-C9 induced 
changes in (a) cell proliferation (trypan blue dye exclusion), (b) cell cycle distribution (FACS) and (c) 
soft agar colony formation.  
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4.4.2.2 HOXC9 expression abrogates neuroblastoma tumor growth in vivo  
Two xenograft mouse model systems were used to assess the effect of Hox-C9 on 
neuroblastoma tumor growth in vivo. First, tumor growth was investigated in neuroblastoma 
cells induced for transgene expression 48h before xenografting. GFP-expressing SK-N-AS 
and IMR-32 control cells formed rapidly growing tumors with mean tumor volumes of 
1905 ± 295 mm
3 
at day 17 and 1323 ± 404 mm
3 
at day 22, respectively. In contrast, tumor 
growth was almost completely abrogated in mice inoculated with HOXC9 expressing SK-N-S 
and IMR-32 (tumor volumes of 79 ± 31 mm
3
 at day 17 and 173 ± 129 mm
3
 at day 22, 
respectively; Figure 16a).  
To investigate the impact of Hox-C9 in already established tumors, SK-N-AS 
HOXC9-off and SK-N-AS GFP-off cells were subcutaneously injected in the lateral thoracic 
wall of athymic Nude- Foxn1
nu 
mice. Transgene expression was induced after the tumor had 
reached a mean tumor volume of 144 ± 41 mm
3 
(120
 
± 25 mm
3 
in the control group and 174 ± 
36 mm
3
 in the HOXC9 group) by switching from standard diet to doxycycline containing diet. 
Induction of transgene expression was started 8 days after tumor inoculation in the control 
group and after 18 to 34 days in the HOXC9 group, indicating a slower initial tumor growth 
probably due to low-level Hox-C9 expression under uninduced conditions (Figure 13b). GFP 
expressing control cells formed tumors that exceeded 1 cm
3
 and had to be sacrificed 10 days 
after transgene induction, while the HOXC9 expressing group formed tumors accounted for 
5.3 ± 2% the tumor volumes of the control group (Figure 16b). 
Histological examination of neuroblastoma xenograft tumors revealed that Hox-C9 
expression led to stroma rich tumors containing less mitotic cells than in GFP expressing 
control tumors, which contained extensive amounts of mitotic cells with atypical mitotic 
figures (Figure 17).  
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Figure 16: HOXC9 re-expression inhibits growth of neuroblastoma cells in vivo. (a) Hox-C9 
expression impedes tumor growth in SK-N-AS and IMR-32 neuroblastoma xenografts (n= 8 mice per 
group). (b) Hox-C9 induction in already established xenograft tumors. Error bars indicate standard 
deviation (SD), p-values (unpaired, two-tailed Students t-test). 
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Figure 17: Histological features of neuroblastoma xenografts. Histological evaluation was done using 
paraffin-embedded sections stained with Meyer’s hematoxylin and eosin. Arrows indicate tumor cells 
with atypical mitotic figures. 
 
 
4.4.3 Hox-C9 induces neuronal differentiation in neuroblastoma  
4.4.3.1 Hox-C9-induced neuronal differentiation of IMR-32 cells is 
accompanied by down-regulation of REST  
Morphological signs of neuronal differentiation were assessed by microscopic examination in 
all three cell lines after HOXC9 re-expression. In IMR-32 cells, HOXC9 re-expression led to a 
neuronal-like phenotype with a large network of cells interconnected by long neurite 
elongations (Figure 18), while similar changes were not observed in the other cell lines. To 
determine whether this morphological alteration induced by Hox-C9 was accompanied by up-
regulation of genes involved in neuronal differentiation, I analyzed expression levels of the 
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neuron-related markers PTN (226-228), NNAT (229), NEFL (52), TRKA (100, 230), DNER 
(231) and NTS (232) by qRT-PCR and microarray analysis. In line with the morphological 
changes, all markers were up-regulated upon HOXC9 re-expression (Figure 19a and b). At the 
same time, the RE1-silencing transcription factor REST, a master negative regular of 
neurogenesis, was down-regulated in Hox-C9-induced IMR-32 cells (Figure 19c and 19d). 
 
 
 
Figure 18: Hox-C9 induces neuronal differentiation in IMR-32 cells. Morphological changes of IMR-
32 cells at 21 days after Hox-C9 and GFP induction. White light images and F-Actin cytoskeleton 
organization (labeled with Rhodamine Phalloidin (red) and counterstained with DAPI (blue)).  
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Figure 19: HOXC9 expression up-regulates neuron-related markers in IMR-32 cells (a) as determined 
by oligonucleotide-microarrays and (b) qRT-PCR. Hox-C9 expression down-regulates REST (c) as 
determined by oligonucleotide-microarrays and (d) qRT-PCR. Error bars indicate SD, p-values 
(unpaired, two-tailed Students t-test). 
 
4.4.4 HOXC9 re-expression induces apoptosis in neuroblastoma 
cell lines 
I next examined whether apoptosis contributes to inhibition of neuroblastoma cell growth 
after HOXC9 re-expression. First, externalization of phosphatidylserine was analyzed by flow 
cytometry using Annexin-V staining. I observed a significant increase of the Annexin-V 
binding fraction in SK-N-AS and CHP-212 cells 168h after HOXC9 re-expression in 
comparison to control cells (Figure 20a). Second, DNA fragmentation was assessed using the 
TUNEL assay in SK-N-AS, IMR-32 and CHP-212 cells. HOXC9 expressing neuroblastoma 
cells showed a significantly higher fraction of cells with fragmented DNA as compared to 
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GFP-expressing controls (Figure 20b). These results were supported by FACS analysis 
following Hox-C9 induction in SK-N-AS, IMR-32 and CHP-212 cells, in which Nicoletti 
labeling and assessment of the fraction of sub-G1 events indicated an accumulation of cells 
with fragmented DNA. In all investigated cell lines, the sub-G1 fraction was significantly 
increased by HOXC9 re-expression as compared to GFP-induced controls (Figure 20c). 
Together, these findings indicate that Hox-C9 affects growth properties in human 
neuroblastoma cells not only by cell cycle regulation but also by induction of apoptosis. 
 
 
Figure 20: Hox-C9 induces apoptosis in neuroblastoma cell lines. (a) Proportion of Annexin-V 
positive cells as determined by FACS. (b) Proportion of cells showing apoptotic nuclei as determined 
by fluorescence microscopy (TUNEL). (c) Proportion of cells with subnormal DNA content as 
determined by FACS.  
 Results 
 
 74 
 
4.4.4.1 Hox-C9 activates the intrinsic pathway of apoptosis 
To further analyze Hox-C9-induced cell death, the expression of pro- and anti-apoptotic 
regulators was examined by immunoblot, qRT-PCR and microarray analysis in HOXC9- 
expressing and control neuroblastoma cells. Apoptotic cell death was associated with a strong 
increase of cytochrome c in the cytosolic fraction of Hox-C9-induced cells (Figure 21a) 
suggesting a loss of mitochondrial membrane potential and involvement of mitochondria in 
Hox-C9-induced cell death. In IMR-32 cells, I observed down-regulation of BCL-2 both on 
the transcript and protein level, while expression levels remained unchanged in SK-N-AS and 
CHP-212 cells (Figure 21a, b and c). In the latter cell lines, however, I observed a marked up-
regulation of BAX mRNA expression upon induction of Hox-C9 (Figure 21b and c). These 
data suggest that apoptosis induced by HOXC9 re-expression may be conferred by a shifted 
BCL-2/BAX ratio as a consequence of either increased expression of pro-apoptotic BAX or 
decreased expression of anti-apoptotic Bcl-2. Subsequently, I investigated whether procaspase 
9, the initial caspase in the mitochondrial apoptotic cascade, is activated upon cytochrome c 
release. I observed an increase of cleaved 35 kDa fragments of activated caspase 9 in all cell 
lines upon HOXC9 re-expression (Figure 21a). In addition, a 37 kDa cleaved fragment of 
caspase 9 was observed in SK-N-AS and CHP-212 cells (Figure 21a), which is indicative of a 
feedback amplification loop induced by activated caspase 3 (233). Finally, I observed an 
increased activation of the downstream effector caspases 3 and 7 in all three cell lines (Figure 
21a) upon HOXC9 re-expression. Together, these data indicate that HOXC9 expression can 
activates the intrinsic apoptosis pathway and thereby triggers neuroblastoma cell death. 
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Figure 21: Hox-C9 induces apoptosis in neuroblastoma cell lines by activating the intrinsic apoptotic 
pathway. (a) Protein expression of Bcl-2, cytosolic cytochrome c, and cleaved caspase 9, caspase 7 
and caspase 3 upon Hox-C9 and GFP induction. (b) BCL-2 and BAX expression in IMR-32 and SK-N-
AS cells following Hox-C9 induction as determined by microarrays. (c) BCL-2 expression in IMR-32 
and BAX expression in SK-N-AS and CHP-212 cells following Hox-C9 induction as determined by 
qRT-PCR. Error bars indicate SD, p-values (unpaired, two-tailed Students t-test). Abbreviation: Casp, 
Caspase.  
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4.4.5 HOXC9 expression affects transcriptional pathways 
regulating differentiation and cell death 
To gain further insights into the biological processes occurring upon HOXC9 re-expression, I 
analyzed gene expression profiles of IMR-32 and SK-N-AS cells after Hox-C9 induction 
using microarrays. I used GO annotations to find classes of genes which are significantly 
overrepresented in gene sets that were either up-regulated or down-regulated after HOXC9 re-
expression. Many GO categories significantly enriched for genes up-regulated in HOXC9-
expressing IMR-32 cells were related to neuronal functions and differentiation, thereby 
reflecting the Hox-C9-associated differentiation phenotype in IMR-32 cells (Figure 22a). Of 
note, I also observed that MYCN is down-regulated upon HOXC9 re-expression in MYCN-
amplified IMR-32 cells (Figure 23a). Accordingly, N-Myc protein levels decreased in both 
HOXC9 expressing IMR-32 and CHP-212 cells (Figure 23b), suggesting that down-regulation 
of MYCN might contribute to the favorable phenotype observed in HOXC9-expressing 
neuroblastoma. In SK-N-AS cells, many GO categories significantly enriched for genes up-
regulated by Hox-C9 were associated with cell death (Figure 22c). These results are well in 
line with the observed phenotypes of these two neuroblastoma cell lines after HOXC9 re-
expression: While growth inhibition mediated by apoptosis is the predominant characteristic 
of HOXC9-expressing SK-N-AS cells, neuronal differentiation is mainly observed in IMR-32 
cells. Complete data tables for significantly differentially expressed genes between HOXC9- 
and GFP-induced SK-N-AS and IMR-32 cells and the complete list of GO annotations are 
available through Kocak et al. (234), Supplementary Table S6.    
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Figure 22: Gene Ontology (GO) annotations for significantly differentially expressed genes. (a) GO 
terms for up-regulated or (b) down-regulated genes by Hox-C9 in IMR-32 cells. (c) GO terms for up-
regulated or (d) down-regulated genes by Hox-C9 in SK-N-AS cells. Only GO terms for “biological 
process” with corrected p-values < 0.01 are shown. GO terms associated with neuronal functions and 
differentiation are highlighted in red, GO terms associated with cell death are highlighted in blue. 
Abbreviation: GO, Gene Ontology.   
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Figure 23: HOXC9 leads to reduced expression of MYCN. (a) MYCN expression in MYCN-amplified 
IMR-32 cells after HOXC9 re-expression as determined by microarrays. (b) N-Myc expression in 
IMR-32 and CHP-212 cells upon Hox-C9 and GFP induction as determined by Western blot analysis. 
+, transgene is weakly expressed under uninduced conditions; ++ transgene is induced by doxycycline 
treatment for 48 h. Abbreviation: Intens, Intensity.  
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5 Discussion  
5.1 Expression patterns of HOX genes in neuroblastoma  
In this study, I report that expression of the majority of class I HOX genes is associated with 
clinical phenotypes of neuroblastoma. HOX genes play essential roles in morphogenesis and 
cell differentiation during embryonic development (103). Since neuroblastoma is an 
embryonal tumor capable of differentiating into less aggressive ganglioneuroblastoma or 
benign ganglioneuroma, it has been suggested that Hox transcription factors may be involved 
in these processes (102, 184). Accordingly, it has been reported that morphological 
differentiation of neuroblastoma cells upon treatment with RA is accompanied by increased 
expression of a number of HOX genes (102, 184, 235). In line with these results, I here show 
that expression of most HOX genes is significantly associated with prognostic markers and 
clinical outcome in primary neuroblastoma, suggesting that HOX genes are essentially 
involved in neuroblastoma pathogenesis.  
The potential relevance of these genes is further emphasized by the finding that a HOX 
gene expression-based classifier was able to accurately predict neuroblastoma patient 
outcome independently of the prognostic markers age at diagnosis, stage of disease and 
amplification status of the proto-oncogene MYCN. I observed that HOX genes of the A, B and 
C cluster were mainly up-regulated in favorable neuroblastoma, while genes of the D cluster, 
particularly HOXD3, HOXD8, HOXD9 and HOXD10, were up-regulated in unfavorable 
tumors. These findings are in contrast to a recent study of Mao et al. (195), who investigated 
the prognostic value of a panel of HOX genes (HOXA9, HOXB9, HOXD1, HOXD8, HOXD9) 
in primary neuroblastoma, and did not observe any correlation of the expression and clinical 
outcome for most of these. The difference between the two studies might be explained by the 
fact that Mao and co-workers examined a limited number of samples comprising metastasized 
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neuroblastoma without MYCN amplification only (24), while a large tumor cohort 
representing the entire spectrum of the disease has been analyzed in my study.  
In another study, the group of Han-Fei Ding showed that induction of Hox-D8, Hox-
D9 and Hox-D10 results in growth arrest and neuronal differentiation in neuroblastoma using 
the cell line BE(2)-C as a model system (185). In addition, Hox-D8 was suggested to mediate 
its functional effects by directly activating Hox-C9, which implicates that HOXD8 and 
HOXC9 expression levels are positively correlated. The expression analysis of primary 
tumors in my study does not support this suggestion, as I observed a modest negative 
correlation of HOXD8 and HOXC9 expression levels (data not shown). These discrepant 
results could be explained by the fact that a single neuroblastoma cell line has been used for 
functional studies of HOXD genes in the study of Zha et al., which probably is not 
representative of the entire biological and clinical spectrum of neuroblastoma. In addition, one 
may speculate that the biological function of these HOX genes may depend on specific 
expression thresholds. This suggestion is supported by specific patterns of survival curves of 
patients stratified according to quartiles of HOXD8, HOXD9 and HOXD10 expression levels 
in my study (Figure 6). For all three genes, patients with low, intermediate-low and 
intermediate-high expression levels had similar outcomes, whereas the outcome of those with 
high expression levels was substantially inferior. These findings may indicate that expression 
of HOXD8, HOXD9 and HOXD10 is of prognostic relevance only if specific expression 
thresholds are exceeded.  
Spatial and temporal co-linearity is a hallmark of clustered HOX genes (236, 237). 
HOX genes located more 5’ in the HOX cluster, such as HOXC9, are expressed later and more 
posterior during early development. In accordance with this embryonic expression pattern of 
HOX genes, I here show a significant correlation of increased HOXC9 expression levels in 
neuroblastomas from abdominal sites in comparison to tumors of the neck and chest. This 
finding contrasts with previous speculations (195), which suggested that HOXC9 expression 
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might be higher in tumors of the neck and thorax because of their association with a better 
outcome (223, 224) and a more differentiated histology (225). Indeed tumors located at the 
neck/chest appear to have a slightly better outcome compared to tumors located at the adrenal 
glands or abdomen (Figure 9b and c). While the correlation of HOXC9 with the primary 
tumor site fits well to the embryonal expression pattern of HOX genes, most of the other 5’ 
located HOX genes do not show such an expression pattern, suggesting that multiple factors 
may influence HOX gene expression in neuroblastoma.   
  
5.2 Expression patterns of HOXC9 in neuroblastoma  
Among all HOX genes, HOXC9 expression was most prominently associated with favorable 
prognostic markers and benefical clinical outcome in neuroblastoma. The prognostic impact 
of HOXC9 is underlined by the fact that this gene was selected in all predictive models 
generated during the training phase of the HOX classifier generation process (Table 22), and 
that it was one of 144 predictive genes of a prognostic classifier reported previously (25). 
Using gene expression data from our group and others, low expression of HOXC9 has also 
been described to be associated with the unfavorable clinical phenotype of neuroblastoma in a 
recent study (195).  
Since genetic and epigenetic changes can lead to altered gene expression and, thereby, 
trigger cancer development, I questioned which genetic or epigenetic factors might influence 
HOXC9 expression in primary neuroblastoma. A gain of chromosome 12, which comprises 
the HOXC9 locus, was associated with elevated HOXC9 transcript levels, suggesting that a 
gene-dosage effect might account for HOXC9 expression differences in neuroblastoma. These 
findings are in line with previous reports showing that numerical chromosomal aberrations 
including chromosome 12 gain (238, 239) are associated with lower stages (205) and better 
outcome in neuroblastoma (240). Diminished HOX gene expression was reported to be 
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associated with promoter hypermethylation in numerous malignancies (155, 163-166) and 
seems to be a major mechanism of HOX gene de-regulation in cancer. By contrast, I neither 
detected hypermethylation of the promoter region of HOXC9 nor inactivating mutations at the 
HOXC9 locus as a potential cause of decreased HOXC9 expression in unfavorable tumors. 
Mao and co-workers (195) showed that the HOXC9 promoter is associated with the chromatin 
silencing marker H3K27me3 in RA-resistant SK-N-AS cells. Whether this finding represents 
a common regulatory mechanism for HOXC9 gene silencing in the unfavorable subgroup of 
neuroblastoma remains to be elucidated. Alternatively, other mechanisms, such as regulatory 
RNA’s (241) or upstream transcriptional regulators (36) may control HOXC9 expression in 
neuroblastoma. In human embryonic stem (ES) cells Myc and Miz-1 control HOX gene 
expression (242), which may represent a further possibility for transcriptional regulation of 
HOXC9 in neuroblastoma. 
 
5.3 The functional relevance of HOXC9 expression in 
neuroblastoma 
5.3.1 HOXC9 leads to neuronal differentiation in IMR-32 cells  
Neuroblastoma is an embryonal tumor with the potential to differentiate into less aggressive 
ganglioneuroblastoma or benign ganglioneuroma, and HOX genes have been suggested to be 
involved in these processes (102, 184). In line with this hypothesis, it has been reported that 
the expression of a number of HOX genes increases by induction of neuroblastoma cell 
differentiation using RA, which is implemented in the post-consolidation therapy of stage 4 
neuroblastoma (243). In this study, I substantiate that Hox-C9 may induce neuronal 
differentiation in a fraction of neuroblastomas. The induction of neuron associated marker 
genes and neurogenesis-like processes by re-expression of HOXC9 in IMR-32 cells points 
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towards a role of HOXC9 in neuroblastoma cell differentiation. In human cells, MYC has been 
shown to repress HOX gene expression to maintain ES cell pluripotency (242). Given the 
inverse correlation of MYCN amplification and HOXC9 expression in our cohort (Figure 8a), 
one may speculate that such a mechanism may also exist in neuroblastoma. Conversely, I 
observed that morphological differentiation of MYCN-amplified IMR-32 cells upon HOXC9 
re-expression is accompanied by decreased MYCN expression. Since down-regulation of 
MYCN is a general feature of neural differentiation (244), it might be possible that Hox-C9 
mediates differentiation by repression of MYCN. In addition, I observed down-regulation of 
REST after HOXC9 re-expression. REST is a well-known master negative regulator of 
neurogenesis (245), and has been reported to be degraded upon RA induced neuroblastoma 
cell differentiation (246). While REST has been described as a potent tumor suppressor gene 
in several non-neural tumors including small cell lung cancer and breast cancer (247, 248), 
oncogenic functions have been described in neuroblastoma (249) and medulloblastoma (250). 
REST expression has been observed in ES cells and neural progenitor cells (251-253), where 
it represses several terminal neuronal differentiation genes (253-255). However, REST down-
regulation in neural progenitors during neurogenesis de-represses its target genes. While 
REST down-regulation is mediated by proteasomal degradation during the differentiation of 
ES cells into neural progenitors, its down-regulation during differentiation of neural 
progenitors into mature neurons occurs by transcriptional repression (255, 256). Taking these 
findings into account, it seems likely that Hox-C9 promotes a more differentiated 
neuroblastoma phenotype by transcriptional repression of REST.  
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5.3.2 HOXC9 suppresses growth of neuroblastoma cells in vitro 
and in vivo  
A consistently low expression of HOXC9 in unfavorable neuroblastomas was observed in our 
patient cohort and led to the suggestion that down-regulation of HOXC9 might mediate a 
selective advantage for tumor cells. By contrast, re-expression of HOXC9 in neuroblastoma 
cell lines showing diminished HOXC9 levels may inhibit features of malignancy. In line with 
this hypothesis, I observed that re-expression of HOXC9 suppressed neuroblastoma cell 
proliferation and induced accumulation of cells in the G0/G1-phase of the cell cycle. In 
support of our hypothesis, Mao and co-workes demonstrated that HOXC9 represses the 
transcription of cyclins and cycline dependent kinases and thereby trigger an G0/G1-phase cell 
cycle arrest in neuroblastoma cell lines (195). The fact that HOXC9 inhibited anchorage 
independent growth and in vivo growth of IMR-32 and SK-N-AS cells further strengthens the 
role of HOXC9 as a tumor suppressor candidate gene. A potential tumor suppressive function 
of HOXC9 in already established xenograft tumors could not be clarified due to limitations of 
the leaky promoter system used in this study. Histological examination of neuroblastoma 
xenograft tumors revealed that Hox-C9 expression resulted in stroma rich xenograft tumors 
containing lower contents of mitotic cells, supporting the hypothesis that Hox-C9 affects cell 
cycle progression in a dominant negative manner (195).  
 
5. 3.3 HOXC9 induces apoptosis in neuroblastoma cells 
The strong effect of Hox-C9 re-expression on neuroblastoma growth arrest observed here and 
by others (195) suggested that additional mechanisms beyond cell cycle arrest may contribute 
to this phenotype. Accordingly, I here provide substantial evidence that Hox-C9 promotes 
apoptosis in neuroblastoma in general, as indicated by a strong increase of the sub-G1 fraction 
and an increase of TUNEL-positive cells after HOXC9 induction in all three cell lines 
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analyzed. I demonstrate that HOXC9 expression activates the intrinsic pathway of apoptosis, 
probably by increasing the BAX:BCL-2 ratio, which in turn may lead to the release of 
cytochrome c from the mitochondria into the cytosol and to activation of the intrinsic cascade 
of caspases. The putative role of HOXC9 in promoting apoptotic processes in neuroblastoma 
is further supported by the results of the GO analysis described here, which correspond to the 
apoptotic phenotype of Hox-C9 expressing neuroblastoma cell lines. The data presented here 
suggest that a combination of G0/G1-phase arrest associated with induction of cell 
differentiation and the initiation of apoptotic processes lead to the favorable phenotype of 
neuroblastoma with high HOXC9 expression. Such a broad spectrum of regulatory effects is 
not uncommon for transcriptional regulators (257-259) and has been described for HOX genes 
in particular (reviewed in (179).  
 
5.4 HOXC9 expression and the association with 
spontaneous tumor regression in neuroblastoma 
Neuroblastoma is an embryonal tumor derived from fetal precursors of the sympathetic 
nervous system, and has the highest frequency of spontaneous regression observed in human 
malignancies. Mass screening studies for neuroblastoma conducted in the 1990’s resulted in a 
substantially increased incidence of neuroblastoma cases. These results led to the suggestion 
that spontaneous regression of neuroblastoma occurs far more often than previously thought, 
and that the cases detected by mass screening studies represent neuroblastomas that would 
have never become clinically evident. It has thus been suggested that spontaneous regression 
may represent a delayed activation of developmentally regulated apoptotic pathways (99, 
100). However, the molecular mechanisms of this peculiar phenomenon have remained 
enigmatic. Since expression of Hox transcription factor genes is tightly regulated during 
embryogenesis and fundamental for a normal embryonic development, I hypothesized a role 
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of these genes in neuroblastoma pathogenesis in general and in spontaneous regression in 
particular. I found that elevated HOXC9 expression is not only associated with favorable 
prognostic markers and beneficial outcome in primary neuroblastoma, but also correlates with 
spontaneous tumor regression. Molecularly, spontaneous regressing neuroblastomas are 
characterized by a near-triploid DNA content and absence of structural chromosomal 
alterations (57, 260). Considering the correlation of high HOXC9 expression with favorable 
molecular characteristics of the tumor, favorable patient outcome and spontaneous regression, 
and its pro-apoptotic function in neuroblastoma cells, I hypothesize that Hox-C9 may 
represent a critical factor for the process of spontaneous regression in neuroblastoma.  
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6 Conclusion  
 
In summary, I here demonstrate that distinct HOX gene expression patterns are associated 
with clinical phenotypes of neuroblastoma. I show that HOXC9 expression does not only 
correlate with favorable prognostic markers and beneficial clinical outcome, but also with 
spontaneous regression in infant neuroblastoma. Re-expression of HOXC9 in neuroblastoma 
cell lines consistently leads to strong growth arrest and activates the intrinsic pathway of 
apoptosis. Taken together, I conclude from these data that HOX genes may contribute to 
neuroblastoma pathogenesis, and that Hox-C9 might be involved in the molecular process of 
spontaneous regression. 
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8 Appendix 
8.1 Abbreviations 
A   Allele 
AA   Amino Acid 
ABD   Abdomen 
aCGH   Array-based Comparative Genomic Hybridization 
AG   Adrenal Glands 
AIG   Anchorage Independent Growth 
ALK   Anaplastic lymphoma kinase  
ALL   Acute Lymphocytic Leukaemia  
AML   Acute Myeloid Leukaemia 
Ampl   Amplicon 
AP   Anterior-Posterior 
BMP   Bone Morphogenetic Protein 
Brdu   5-bromo-2’-deoxyuridine 
CCHS   Congenital Central Hypoventilation Syndrome  
CD   Codon 
CI   Confidence Interval 
CO   Coordinate 
Cod   coding   
CV   Cross Validation 
DAPI   2,4-diamidino-2-phenylindole 
Del   Deletion 
Diff   Differentiation  
Dir   Direction  
Dox   Doxycycline 
EFS   Event-free survival  
ES   Embryonic Stem  
FACS   Fluorescence Activated Cell Sorting  
Fav   Favorable 
FCS   Fetal Calf Serum 
FGF   Fibroblast Growth Factors 
For   forward 
Freq   Frequency 
 Appendix 
 
 106 
GN   Ganglioneuroma 
GNB   Ganglioneuroblastoma  
GO   Gene Ontology 
GOTM   Gene Ontology Tree Machine 
HR   High-Risk  
HRE   HOX Responsive Element 
HRP   horseradish peroxidase  
HUVEC  Human Umbilical Vein Endothelial Cell 
IGV   Integrative Genomics Viewer 
INRG   International Neuroblastoma Risk Group 
INSS    International Neuroblastoma Staging System  
Intr   Intronic 
IR   Intermediate-Risk  
LR   Low-Risk  
NB   Neuroblastoma  
NC   Neural Crest 
NK/C   Neck/Chest 
Norm   Normal 
OS   Overall Survival  
PAM   Predictive Algorithm of Microarray 
PcG   Polycomb Group  
PI   Propidium Iodide 
qRT-PCR  Quantitative real-time reverse transcriptase-polymerase chain reaction  
RA   Retinoic Acid 
REG   Region 
Rev   Reverse 
RIN   RNA integrity number  
rtTA   reverse tetracycline-controlled Transactivator 
S   Special 
SA   Sympathoadrenal 
SD   Standard Deviation 
SMC   Smooth Muscle Cells 
SNS   Sympathetic Nervous System 
SVM   Support Vector Machine 
TALE    Three-Amino Acid-Loop-Extension 
Temp   Temperature  
TRITC   Tetramethylrhodamine Isothiocyanate 
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TrxG   Trithorax Group 
TUNEL  (TdT)-mediated dUTP Nick End Labeling 
Unfav   Unfavorable 
WGA    Whole Genome Amp 
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